[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 689
1. Tang J, Shao W, Dorak MT, Li Y, Miike R, Lobashevsky E, Wiencke JK, Wrensch M, Kaslow RA, Cobbs CS: Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev; 2005 Aug;14(8):2040-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme.
  • We examined the relationships of human leukocyte antigen (HLA) and related polymorphisms to glioblastoma multiforme in adult Caucasians (non-Hispanic Whites) from the San Francisco Bay area.
  • For 155 glioblastoma multiforme patients and 157 control subjects closely matched by ethnicity, age, and gender, PCR-based techniques resolved alleles at HLA-A, -B, -C, and -DRB1 loci along with short tandem repeat polymorphisms of MICA exon 5 and TNFb.
  • By multivariable logistic regression, B*13 and the B*07-Cw*07 haplotype were positively associated with glioblastoma multiforme (P=0.01 and <0.001, respectively), whereas Cw*01 was the only variant showing a negative association (P=0.05).
  • Among glioblastoma multiforme patients, progression to death after diagnosis was slower in those with A*32 (relative hazard, 0.45; P<0.01) and faster in those with B*55 (relative hazard, 2.27; P<0.01).
  • Thus, both the occurrence and the prognosis of glioblastoma multiforme could be associated with specific but different HLA genotypes.
  • B*07 and the B*07-Cw*07 haplotype are much more common in Caucasians than other ethnic groups in the U.S., which may partially explain the higher incidence of glioblastoma multiforme in Caucasians.
  • [MeSH-major] Biomarkers, Tumor / genetics. Glioblastoma / genetics. HLA Antigens / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Female. Genetic Variation. Genotype. Humans. Male. Microsatellite Repeats. Polymerase Chain Reaction. Polymorphism, Genetic. Prognosis. San Francisco

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103458.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA097247; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens
  •  go-up   go-down


2. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS Sr, Riggins GJ: PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res; 2006 Oct;4(10):709-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
  • Recently, a large-scale mutational analysis of eight PI3K and eight PI3K-like genes revealed somatic mutations in PIK3CA, which encodes the p110alpha catalytic subunit of class IA PI3K, in several types of cancer, including glioblastoma multiforme.
  • Given this disparity and to address the relation of patient age to mutation frequency, we examined 10 exons of PIK3CA in 73 glioblastoma samples by PCR amplification followed by direct DNA sequencing.
  • Of the primary tumors, PIK3CA mutations were identified in 21% and 17% of pediatric and adult samples, respectively.
  • [MeSH-major] Genetic Predisposition to Disease. Glioblastoma / genetics. Mutation. Phosphatidylinositol 3-Kinases / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050665.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


3. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, Razavi P, Patoka J, Wiencke JK, Bondy ML, Wrensch M: Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1118-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between polymorphisms in DNA repair genes and glioblastoma.
  • A pooled analysis was conducted to examine the association between select variants in DNA repair genes and glioblastoma multiforme, the most common and deadliest form of adult brain tumors.
  • Genetic data for approximately 1,000 glioblastoma multiforme cases and 2,000 controls were combined from four centers in the United States that have conducted case-control studies on adult glioblastoma multiforme, including the National Cancer Institute, the National Institute for Occupational Safety and Health, the University of Texas M. D.
  • The C allele of the PARP1 rs1136410 variant was associated with a 20% reduction in risk for glioblastoma multiforme (odds ratio(CT or CC), 0.80; 95% confidence interval, 0.67-0.95).
  • A 44% increase in risk for glioblastoma multiforme was found for individuals homozygous for the G allele of the PRKDC rs7003908 variant (odds ratio(GG), 1.44; 95% confidence interval, 1.13-1.84); there was a statistically significant trend (P = 0.009) with increasing number of G alleles.
  • Few studies have reported on the associations between variants in DNA repair genes and brain tumors, and few specifically have examined their impact on glioblastoma multiforme.
  • Our results suggest that common variation in DNA repair genes may be associated with risk for glioblastoma multiforme.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7136-41 [16627622.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):145-55 [16598069.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):197-205 [17200355.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):122-6 [17214964.001]
  • [Cites] Neuroscience. 2007 Apr 14;145(4):1267-72 [17084037.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):1906-13 [17389609.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):1-5 [17999957.001]
  • [Cites] Hum Mol Genet. 2008 Mar 15;17(6):800-5 [18048407.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):484-9 [18349266.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1368-73 [18559551.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):843-7 [10952103.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Genet Epidemiol. 2001 Feb;20(2):258-70 [11180451.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Maturitas. 2001 Feb 28;38(1):17-22; discussion 22-3 [11311581.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] Neurology. 2001 Nov 27;57(10):1751-5 [11723257.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):22-33 [11900249.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Toxicology. 2003 Nov 15;193(1-2):3-34 [14599765.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4378-84 [15205355.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5560-3 [15313891.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6344-8 [15342424.001]
  • [Cites] Cell. 1986 Mar 28;44(6):913-23 [2420469.001]
  • [Cites] Nucleic Acids Res. 1987 Nov 25;15(22):9195-213 [3684592.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Cells. 1990 Oct;2(10):311-20 [2282248.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4760-3 [8062276.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2415-8 [7852297.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1261-6 [7882319.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):17-23 [8583241.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8285-94 [8626523.001]
  • [Cites] Methods Enzymol. 1996;272:199-210 [8791778.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 1;100(1):77-83 [9406586.001]
  • [Cites] Environ Mol Mutagen. 1999;33(1):3-20 [10037319.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Genome Res. 2005 Feb;15(2):269-75 [15687290.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):722-6 [15705867.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2363-72 [15834925.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):495-507 [16212814.001]
  • [Cites] Am J Hum Genet. 2006 Jan;78(1):15-27 [16385446.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • (PMID = 19318434.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA070917; United States / NCI NIH HHS / CA / R01 CA052689-18; United States / NCI NIH HHS / CA / R01 CA052689-19; United States / NCI NIH HHS / CA / CA097257-080001; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / CA052689-19; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA070917; United States / NCI NIH HHS / CA / P50CA097257; United States / NCI NIH HHS / CA / R01CA52689; United States / NCI NIH HHS / CA / P50 CA097257-080001; United States / NCI NIH HHS / CA / R01 CA070917-09; United States / NCI NIH HHS / CA / CA052689-18; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS96659; NLM/ PMC2667563
  •  go-up   go-down


Advertisement
4. Chong PK, Loo AV: Visual epilepsy in glioblastoma multiforme. Med J Malaysia; 2008 Dec;63(5):406-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visual epilepsy in glioblastoma multiforme.
  • We report a 33-year-old Chinese gentleman who presented with visual epilepsy and symptoms of raised intracranial pressure in which clinical examination revealed normal visual fields and acuity despite Magnetic Resonance Imaging (MRI) brain showing large contrast enhancing mass at the right occipital lobe.
  • Craniotomy and excision of tumour was done and the histology confirmed glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / pathology. Epilepsies, Partial / pathology. Glioblastoma / pathology. Hallucinations / pathology. Occipital Lobe / pathology
  • [MeSH-minor] Adult. Cranial Irradiation. Craniotomy. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19803301.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


5. Lasky JL 3rd, Choe M, Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther; 2009 Dec;4(4):298-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells in pediatric brain tumors.
  • Central nervous system (CNS) tumors remain the leading cause of death among pediatric neoplasms.
  • Although standard therapies cure many pediatric CNS tumors, the long-term cognitive and physical consequences of these therapies are devastating.
  • Although recent studies have focused on molecular mechanisms that underlie the initiation and progression of adult glioblastoma multiforme (GBM), these tumors differ phenotypically and at a molecular level from pediatric brain tumors.
  • Recent investigations have identified a stem cell population, termed "brain tumor stem cells" (BTSC) within the heterogeneous cell populations that comprise malignant brain tumors which may be partly responsible for the resistance to current therapies.
  • By exploiting molecular differences present within these heterogeneous populations of brain tumor cells, we may be able to achieve specific eradication of BTSC and long-lasting remissions, while causing less toxicity to normal tissues.
  • In this review, we describe the issues surrounding the identification and characterization of BTSC, the molecular biology of BTSC for different pediatric brain tumors, and suggest future avenues for the development of treatments for this devastating disease.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Medulloblastoma / pathology. Neoplastic Stem Cells / pathology. Optic Nerve Glioma / pathology
  • [MeSH-minor] Adult Stem Cells / pathology. Biomarkers / metabolism. Cell Differentiation. Chemotherapy, Adjuvant. Child. Humans. Surgical Procedures, Operative


6. Demir MK, Hakan T, Akinci O, Berkman Z: Primary cerebellar glioblastoma multiforme. Diagn Interv Radiol; 2005 Jun;11(2):83-6
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cerebellar glioblastoma multiforme.
  • Primary glioblastoma multiforme of cerebellar hemispheres in adults is a rare condition.
  • Most of them result from dedifferentiation of astrocytoma to glioblastoma.
  • [MeSH-major] Cerebellar Neoplasms / radiography. Glioblastoma / radiography
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Nausea / etiology. Neurologic Examination. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957093.001).
  • [ISSN] 1305-3825
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


7. Mattos JP, Marenco HA, Campos JM, Faria AV, Queiroz LS, Borges G, Oliveira Ed: Cerebellar glioblastoma multiforme in an adult. Arq Neuropsiquiatr; 2006 Mar;64(1):132-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar glioblastoma multiforme in an adult.
  • Cerebellar glioblastoma multiforme (GBM) is a rare tumor.
  • In conjunction, we present a literature review including particular issues, clinical data, advances in imaging studies, pathological characteristics, treatment options and the behavior of such malignant tumor.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellum / pathology. Glioblastoma / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622570.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 16
  •  go-up   go-down


8. Hur H, Jung S, Jung TY, Kim IY: Cerebellar glioblastoma multiforme in an adult. J Korean Neurosurg Soc; 2008 Apr;43(4):194-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar glioblastoma multiforme in an adult.
  • Primary cerebellar glioblastoma multiforme (GBM) is a rare tumor in adults that accounts for just 1% of all cases of GBM.
  • After operation, glioblastoma was histologically confirmed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Interv Radiol. 2005 Jun;11(2):83-6 [15957093.001]
  • [Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Mar;16(3):583-9 [7793385.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jan-Feb;15(1):160-2 [1987190.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):915-8 [2824720.001]
  • [Cites] J Neurosurg Sci. 1985 Jan-Mar;29(1):43-50 [2999352.001]
  • [Cites] Arq Neuropsiquiatr. 1985 Mar;43(1):102-7 [2990393.001]
  • [Cites] J Neurooncol. 1989 Nov;7(4):339-44 [2555454.001]
  • [Cites] Tumori. 1989 Dec 31;75(6):626-9 [2559527.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):251-5 [3309714.001]
  • [Cites] Br J Radiol. 1985 May;58(689):480-2 [4063702.001]
  • [Cites] Semin Roentgenol. 1990 Jul;25(3):263-78 [2385809.001]
  • [Cites] Semin Roentgenol. 1990 Apr;25(2):155-73 [2349487.001]
  • [Cites] J Neurosurg. 1983 Apr;58(4):589-92 [6298382.001]
  • [Cites] Surg Neurol. 1983 Apr;19(4):373-8 [6301087.001]
  • [Cites] Arq Neuropsiquiatr. 1981 Sep;39(3):350-4 [6275825.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):308-11 [6282439.001]
  • [Cites] Acta Neurochir (Wien). 1980;53(1-2):107-16 [6254346.001]
  • [Cites] Surg Neurol. 1976 Jun;5(6):341-3 [180621.001]
  • [Cites] J Chin Med Assoc. 2004 Jun;67(6):301-4 [15366408.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Sep;23(8):1369-77 [12223380.001]
  • [Cites] J Neurosurg. 1999 Mar;90(3):546-50 [10067927.001]
  • (PMID = 19096643.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588262
  • [Keywords] NOTNLM ; Cerebellum / Differential diagnosis / Glioblastoma multiforme / Pathogenesis
  •  go-up   go-down


9. Potter NE, Phipps K, Harkness W, Hayward R, Thompson D, Jacques TS, Harding B, Thomas DG, Rees J, Darling JL, Warr TJ: Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ. Exp Cell Res; 2009 Oct 1;315(16):2835-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Astrocytoma derived short-term cell cultures retain molecular signatures characteristic of the tumour in situ.
  • We have characterised gene expression changes induced by short-term culture in astrocytoma in order to determine whether derived short-term cell cultures are representative of the tumour in situ.
  • We have used the Affymetrix GeneChip U133A to generate gene expression profiles of 6 paediatric pilocytic astrocytoma (PA) biopsies and derived short-term cell cultures and 3 adult glioblastoma multiforme (GBM) biopsies and derived short-term cultures.
  • This gene cohort can distinguish PA and GBM tumours, regardless of the sample source, suggesting that astrocytoma derived short-term cultures do retain key aspects of the global tumour expression profile and are representative of the tumour in situ.
  • Furthermore, these genes are involved in pathways and functions characteristic of adult GBM including VEGF signalling, hypoxia and TP53 signalling.
  • [MeSH-major] Astrocytoma. Biomarkers, Tumor / metabolism. Brain Neoplasms. Tumor Cells, Cultured / metabolism
  • [MeSH-minor] Adult. Animals. Child. Cluster Analysis. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523942.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Tunici P, Yu JS: Pituitary adenoma stem cells. Methods Mol Biol; 2009;568:195-201
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The identification of a subpopulation of brain tumor cells with potent tumorigenic capacity strengthens the cancer stem cell hypothesis of the origin of the tumors that has recently attracted the attention of many researchers.
  • Reports have been published on the identification of tumor cells with stem cells characteristics in different types of tumors (acute myelogenic leukemia, breast cancer, prostate cancer, bone sarcomas, liver cancer, and melanomas).
  • We and other groups have previously reported the isolation of cancer stem cells from adult glioblastoma multiforme.
  • In vivo they give a tumor that recapitulates the characteristics of the tumor in the patient.
  • More recently we have isolated tumor stem-like cells also from benign tumors like pituitary adenomas.
  • The immunocytochemical analysis revealed that pituitary tumor stem-like cells are positives for nestin and, when grown for ten days in differentiation medium they express GFAP, BIII tubulin, and S-100.
  • In vitro tumor stem-like cells derived from a patient with a somatotroph adenoma showed high production of growth hormone and prolactin, while cells derived from the same patient but grown in presence of fetal bovine serum showed no production of hormones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582428.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


11. Jimenez Caballero PE, Mollejo Villanueva M, Marsal Alonso C: [Gliomatosis cerebri: evolution to glioblastoma multiforme]. Neurologia; 2007 Jul-Aug;22(6):395-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gliomatosis cerebri: evolution to glioblastoma multiforme].
  • [Transliterated title] Gliomatosis cerebri: evolución a glioblastoma multiforme.
  • The brain magnetic resonance imaging showed hyperintense lesions in T2 suggestive of gliomatosis cerebri, this being confirmed with the brain biopsy.
  • Several months later, he suffered rapid clinical deterioration, observing the development of a glioblastoma multiforme over the lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Multiple Primary / pathology. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610168.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 25
  •  go-up   go-down


12. Tramacere F, Gianicolo E, Serinelli M, Bambace S, De Luca M, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Distante A, Portaluri M: [Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"]. Clin Ter; 2008 Jul-Aug;159(4):233-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"].
  • [Transliterated title] Multivariate analysis of prognostic factors and survival inpatients with "glioblastoma multiforme".
  • PURPOSE: The aim of this study was to evaluate the survival of patients with "glioblastoma multiforme", to analyse the prognostic factors influencing the survival rate and to review recent results in the literature.
  • Among the factors under investigation we ascertained that sex, chemotherapy, conformal treatment, surgery, and the choice of the irradiation area (whole brain or only the involved field) did not influence the survival in a statistically significant manner.
  • [MeSH-major] Brain Neoplasms / mortality. Glioblastoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776979.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


13. Hernández-Reyna R, Medellín-Sánchez R, Cerda-Flores RM, Calderón-Garcidueñas AL: [Survival pronostic factors in Mexican patients with multiforme glioblastoma]. Rev Med Inst Mex Seguro Soc; 2010 Mar-Apr;48(2):121-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival pronostic factors in Mexican patients with multiforme glioblastoma].
  • [Transliterated title] Factores pronósticos de supervivencia en pacientes mexicanos con glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioblastoma / mortality. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cross-Sectional Studies. Female. Humans. Male. Mexico. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20929613.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


14. Seif FE, Azar S, Barake M, Sawaya R: Hypercalcemia in glioblastoma multiforme. Neuro Endocrinol Lett; 2006 Aug;27(4):547-8
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcemia in glioblastoma multiforme.
  • We report a case of a previously healthy man presenting with glioblastoma multiforme .
  • This is the first reported case of hypercalcemia associated with glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Hypercalcemia / etiology
  • [MeSH-minor] Adult. Calcitriol / blood. Calcium / blood. Humans. Male. Parathyroid Glands / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892004.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] FXC9231JVH / Calcitriol; SY7Q814VUP / Calcium
  •  go-up   go-down


15. Ances BM, Danish SF, Kolson DL, Judy KD, Liebeskind DS: Cerebral gumma mimicking glioblastoma multiforme. Neurocrit Care; 2005;2(3):300-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral gumma mimicking glioblastoma multiforme.
  • This article reports an unusual case of a syphilitic gumma with a clinical and radiographical presentation initially suggestive of glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiography. Glioblastoma / pathology. Glioblastoma / radiography. Neurosyphilis / pathology. Neurosyphilis / radiography
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16159080.001).
  • [ISSN] 1541-6933
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Al-Barbarawi MM, Qudsieh SM, Ghazzawi MA, Smith SF: Glioblastoma multiforme of the cerebellum. Neurosciences (Riyadh); 2009 Jan;14(1):84-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the cerebellum.
  • Glioblastoma multiforme (GBM) is a highly malignant glial tumor seen commonly in the cerebral hemispheres, but rarely encountered in the cerebellum.
  • It may occur at any age, but is seen more often in adult age groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048582.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


17. Amini A, Schmidt RH, Salzman KL, Chin SS, Couldwell WT: Glioblastoma multiforme of the pineal region. J Neurooncol; 2006 Sep;79(3):307-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the pineal region.
  • Glioblastoma multiforme (GBMs) tumors are exceedingly rare tumors in the pineal region.
  • Pineal region GBM seems to be a very aggressive tumor with a high rate of leptomeningeal and ependymal metastatic disease.
  • Glioblastoma should be considered in the differential diagnosis of the pineal region tumors, especially when evidence of leptomeningeal or ependymal metastatic disease is present.
  • [MeSH-major] Brain / pathology. Glioblastoma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / etiology. Tomography, X-Ray Computed. Vision Disorders / etiology. Vomiting / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645719.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Birbilis TA, Matis GK, Eleftheriadis SG, Theodoropoulou EN, Sivridis E: Spinal metastasis of glioblastoma multiforme: an uncommon suspect? Spine (Phila Pa 1976); 2010 Apr 1;35(7):E264-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal metastasis of glioblastoma multiforme: an uncommon suspect?
  • OBJECTIVE: To report a case and review the literature on glioblastoma multiforme (GBM) with drop-like metastasis to the spine.
  • SUMMARY OF BACKGROUND DATA: GBM constitutes the most common adult malignant brain tumor with poor prognosis.
  • CONCLUSION: Spinal metastases should be commonly suspected in patients with a history of intracranial GBM who complain about symptoms not explained by the primary lesion.Glioblastoma multiforme (GBM) was first described by Rudolph Virchow in 1863 and represents the most common and most malignant tumor of the cerebral hemispheres, usually arising between the ages of 40 and 60 years.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Pineal Gland / pathology. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195200.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, Larocca LM: Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer; 2008 Dec 15;123(12):2955-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.
  • Alterations in the signal transduction pathways are key mechanisms in the pathogenesis of de novo glioblastoma multiforme (GBM), which are also involved in the resistance to chemo- and radiotherapy.
  • Our data suggest that methylation of SOCS3 may be involved in the pathogenesis of GBM and in the resistance of this neoplasm to conventional treatment.
  • [MeSH-major] DNA Methylation. Glioblastoma / metabolism. Suppressor of Cytokine Signaling Proteins / metabolism
  • [MeSH-minor] Adult. Aged. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Promoter Regions, Genetic. RNA, Messenger / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18770864.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SOCS1 protein, human; 0 / SOCS2 protein, human; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


20. Haynik DM, Roma AA, Prayson RA: HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):56-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu expression in glioblastoma multiforme.
  • Although information is limited, one study suggested that 15% of glioblastoma multiforme (GBM) express HER-2/neu by immunohistochemistry (IHC); gene amplification by fluorescence in situ hybridization (FISH) was not investigated.
  • Initial surgery involved tumor debulking or subtotal resection in 34 patients.
  • At follow-up (range 1.0 to 49.5 mo, mean 10.5 mo), 40 patients died with tumor and 4 patients were lost to follow-up.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857831 for PMID:17536308 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536308.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doğan AK, Akyüz F: Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON; 2006 Jan-Mar;11(1):39-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative hypofractionated radiotherapy in glioblastoma multiforme.
  • PURPOSE: To evaluate the safety and efficacy of hypofractionated radiotherapy (HRT) in glioblastoma multiforme (GM) patients in terms of overall and progression-free survival.
  • PATIENTS AND METHODS: Adult patients with GM were prospectively treated with HRT after total, subtotal or partial tumor excision.
  • HRT was applied 3 days a week with a tumor dose of 3.33 Gy per fraction.
  • The tumor was multifocal in one (5%) case.
  • The types of operations used were total tumor excision 10(50%) cases, subtotal excision 5 (25%) cases and partial excision 5 (25%) cases.
  • Acute toxicity was minimal and only one HRT patient had late toxicity (brain necrosis).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Pilot Projects. Postoperative Period. Prognosis. Prospective Studies. Radiotherapy Planning, Computer-Assisted. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318950.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


22. Kaneshiro D, Kobayashi T, Chao ST, Suh J, Prayson RA: Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):512-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q deletions in glioblastoma multiforme.
  • In glioblastoma multiforme (GBM), the impact on prognosis of these alterations in GBM is unclear.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19602970.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol; 2007 Oct 20;25(30):4722-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
  • PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months.
  • After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab.
  • One patient developed a CNS hemorrhage, which occurred in his 10th cycle.
  • CONCLUSION: Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Apr;5(4):186-7 [18285760.001]
  • [CommentIn] J Clin Oncol. 2007 Oct 20;25(30):4705-6 [17947716.001]
  • [CommentIn] J Clin Oncol. 2008 Nov 10;26(32):5304-5; author reply 5305 [18854564.001]
  • [CommentIn] Nat Clin Pract Neurol. 2008 May;4(5):242-3 [18212790.001]
  • [CommentIn] J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013 [18281677.001]
  • (PMID = 17947719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 4 R37 CA11898; United States / NCI NIH HHS / CA / 5 P50 CA108786; United States / NINDS NIH HHS / NS / 5 P50 NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


24. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science; 2008 Sep 26;321(5897):1807-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated genomic analysis of human glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer.
  • To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples.
  • These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854877 for PMID:18772396 [PharmGKB] .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]
  • [Cites] J Comput Chem. 2004 Oct;25(13):1605-12 [15264254.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] J Comp Neurol. 1973 Mar 15;148(2):211-6 [4700508.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Biotechniques. 2008 Jul;45(1):81-94 [18611170.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):508-12 [11981567.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2495-9 [8669813.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Mol Biol Evol. 1998 Dec;15(12):1674-84 [9866202.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):31-3 [16369550.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):360-70 [16575211.001]
  • [Cites] Methods Mol Biol. 2007;356:319-50 [16988414.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):709-14 [17050665.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):27-34 [17646934.001]
  • [Cites] Genome Res. 2007 Sep;17(9):1304-18 [17693572.001]
  • [Cites] Free Radic Biol Med. 2007 Oct 15;43(8):1197-207 [17854715.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Cell. 2008 May 2;133(3):523-36 [18423832.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • (PMID = 18772396.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NINDS NIH HHS / NS / NS052507; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R37 CA057345-13; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R37 CA057345-18; United States / NCI NIH HHS / CA / CA09547; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA062924-160017; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NCI NIH HHS / CA / CA057345-13; United States / NCI NIH HHS / CA / P50 CA062924-160017; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / CA11898; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA057345-18; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NINDS NIH HHS / NS / 5P50-NS-20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ NIHMS105586; NLM/ PMC2820389
  •  go-up   go-down


25. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, German Glioma Network: Long-term survival with glioblastoma multiforme. Brain; 2007 Oct;130(Pt 10):2596-606
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with glioblastoma multiforme.
  • The median survival of glioblastoma patients is approximately 12 months.
  • To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular analysis of 55 primary glioblastoma long-term survivors recruited at the six clinical centres of the German Glioma Network and one associated centre.
  • Comparison of these data with results from an independent series of 141 consecutive unselected glioblastoma patients registered in the German Glioma Network revealed significantly more frequent MGMT hypermethylation in the long-term survivor group.
  • Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. DNA, Neoplasm / genetics. Female. Genes, erbB-1. Humans. Karnofsky Performance Status. Loss of Heterozygosity. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Prognosis. Risk Factors. Survivors. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785346.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 105
  •  go-up   go-down


26. Roma AA, Prayson RA: Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol; 2005 Dec;9(6):307-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in 90 patients with glioblastoma multiforme.
  • Fascin immunohistochemical analysis was performed in 90 glioblastoma multiforme, including 53 males and 37 females (mean age, 58.3 years).
  • Nineteen tumors showed more than 75% positive staining tumor cells, 14 tumors had more than 50% to 75% staining, 23 tumors had more than 25% to 50% staining, 26 tumors had more than 5% to 25% staining, and 8 tumors had less than 5% staining.
  • In comparison, 9 of 11 low-grade astrocytomas had 50% or less staining for fascin.
  • Higher grade tumors generally expressed a greater degree of fascin staining.
  • There was no obvious correlation with the extent of staining and survival among glioblastoma multiforme.
  • Fascin may play a role in tumor cell infiltration.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioblastoma / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / metabolism. Astrocytoma / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308158.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


27. Mulholland PJ, Fiegler H, Mazzanti C, Gorman P, Sasieni P, Adams J, Jones TA, Babbage JW, Vatcheva R, Ichimura K, East P, Poullikas C, Collins VP, Carter NP, Tomlinson IP, Sheer D: Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle; 2006 Apr;5(7):783-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme.
  • Glioblastoma multiforme is the most common tumor arising in the central nervous system.
  • In this study, we identify copy number changes in a series of glioblastoma multiforme tumors and cell lines by applying high-resolution microarray comparative genomic hybridization.
  • [MeSH-major] Chromosome Deletion. Gene Expression Profiling. Genome, Human / genetics. Glioblastoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 7 / genetics. Cytogenetics. Female. Gene Dosage / genetics. Gene Expression. Genomics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nucleic Acid Hybridization

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16582634.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A3585; United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C: Glioblastoma multiforme with long term survival. Neurol India; 2005 Sep;53(3):329-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme with long term survival.
  • Glioblastoma multiforme (GBM) Patients generally have a dismal prognosis, with median survival of 10-12 months.
  • [MeSH-major] Glioblastoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Survivors


29. Secer HI, Dinc C, Anik I, Duz B, Gonul E: Glioblastoma multiforme of the lateral ventricle: report of nine cases. Br J Neurosurg; 2008 Jun;22(3):398-401
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme of the lateral ventricle: report of nine cases.
  • Glioblastoma multiforme is the most common lethal primary central nervous system (CNS) tumour in adults and they are rarely seen as primary intraventricular tumours.
  • We present nine cases with lateral ventricle glioblastoma multiforme treated in our department.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Glioblastoma / surgery. Lateral Ventricles / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568728.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Serum samples from 61 newly diagnosed patients with brain tumours and 50 age- and sex-matched non-tumour controls were analysed by ELISA for circulating levels of interleukin-12 (IL-12p70 and p40) and interleukin-10 (IL-10); pivotal Th1 and Th2 cytokines, respectively.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • This study shows that patients with advanced primary intracranial malignancies have decreased circulating IL-12 and increased circulating IL-10, demonstrating that brain tumours have a major systemic effect on the immune system.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged


31. Tunca B, Bekar A, Cecener G, Egeli U, Vatan O, Tolunay S, Kocaeli H, Aksoy K: Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J Neurooncol; 2007 May;82(3):263-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) represents the most common and aggressive type of primary neoplasms of the central nervous system.
  • The PTEN (phosphatase, tensin homologue, deleted on chromosome TEN; MIM # 601728) tumor suppressor gene has an essential biological role in the formation of glioblastomas.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Mutation. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Polymorphism, Single-Stranded Conformational. Turkey

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151929.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


32. Taha M, Ahmad A, Wharton S, Jellinek D: Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis. Br J Neurosurg; 2005 Aug;19(4):348-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-cranial metastasis of glioblastoma multiforme presenting as acute parotitis.
  • We present an unusual case of extracranial metastasis of glioblastoma multiforme (GBM) to the parotid gland and cervical lymph nodes.
  • This case illustrates how GBM behaves in an aggressive manner even outside the CNS.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Parotid Neoplasms / secondary. Parotitis / etiology
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455543.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Iacob G, Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life; 2009 Oct-Dec;2(4):386-93
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current data and strategy in glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors.
  • Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Chromosome Mapping. Diagnosis, Differential. Gene Amplification. Humans. Middle Aged. Mutation. Oncogenes. PTEN Phosphohydrolase / deficiency. PTEN Phosphohydrolase / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Sep;3(9):E1 [17805242.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Hum Gene Ther. 2003 Sep 1;14(13):1247-54 [12952596.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):1-8 [14712205.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 [15184253.001]
  • [Cites] J Neurosurg. 1976 Apr;44(4):442-8 [176331.001]
  • [Cites] Nature. 1980 Dec 25;288(5792):724-7 [6256643.001]
  • [Cites] Carcinogenesis. 1985 Jun;6(6):883-6 [4006075.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;42:187-92 [3189008.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 25;17(16):6581-90 [2780288.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):323-31 [1686725.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79 [7673356.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):453-61 [9509295.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):79-89 [15847978.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):198-206 [15865885.001]
  • [Cites] Neurologist. 2005 Nov;11(6):362-5 [16286879.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):337-43 [16520474.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):1025-34 [18667747.001]
  • [Cites] J Med Life. 2009 Oct-Dec;2(4):386-93 [20108752.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • (PMID = 20108752.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC3019011
  •  go-up   go-down


34. Bohman LE, Gallardo J, Hankinson TC, Waziri AE, Mandigo CE, McKhann GM 2nd, Sisti MB, Canoll P, Bruce JN: The survival impact of postoperative infection in patients with glioblastoma multiforme. Neurosurgery; 2009 May;64(5):828-34; discussion 834-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The survival impact of postoperative infection in patients with glioblastoma multiforme.
  • METHODS: A single-center operative experience accumulated over 10 years was examined to evaluate whether postoperative infections conferred a survival advantage in patients with glioblastoma multiforme.
  • CONCLUSION: In this single-center study, postoperative infection did not confer any survival advantage in patients with glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Glioblastoma / mortality. Neurosurgical Procedures / adverse effects. Postoperative Complications / mortality
  • [MeSH-minor] Adult. Aged. Bacterial Infections / classification. Bacterial Infections / etiology. Bacterial Infections / mortality. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404146.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Nieder C, Grosu AL, Astner S, Molls M: Treatment of unresectable glioblastoma multiforme. Anticancer Res; 2005 Nov-Dec;25(6C):4605-10
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unresectable glioblastoma multiforme.
  • Uncertainty exists about the adequate treatment of adult patients with unresectable, primary, biopsy-proven glioblastoma multiforme (GBM), because the different options for this group of patients have not been evaluated in randomized clinical trials to date.
  • With different radiochemotherapy approaches, the median survival was approximately 5 months in recursive partitioning analysis (RPA) class VI, but 8-14 months in classes IV and V Thus, careful patient selection is necessary to avoid overtreatment in prognostically unfavorable groups with unresectable GBM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334150.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 34
  •  go-up   go-down


36. Showalter TN, Andrel J, Andrews DW, Curran WJ Jr, Daskalakis C, Werner-Wasik M: Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):820-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal glioblastoma multiforme: prognostic factors and patterns of progression.
  • PURPOSE: To assess the progression patterns in patients with multifocal glioblastoma multiforme who had undergone whole brain radiotherapy (WBRT), the historical standard, versus three-dimensional conformal radiotherapy, and to identify predictive treatment and pretreatment factors.
  • METHODS AND MATERIALS: The records of 50 patients with multifocal glioblastoma multiforme treated with RT were reviewed.
  • On the basis of the progression pattern, we do not recommend WBRT as a mandatory component of the treatment of multifocal glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Cranial Irradiation / methods. Disease Progression. Humans. Middle Aged. Prognosis. Proportional Hazards Models. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1335; author reply 1335 [17967325.001]
  • (PMID = 17499453.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L: Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys; 2005 Jul 15;62(4):1133-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
  • PURPOSE: In this study, we assess the efficacy of GliaSite brachytherapy in the treatment of patients with recurrent glioblastoma multiforme (GBM).
  • METHODS AND MATERIALS: Between 1999 and 2004, 24 patients with recurrent glioblastoma multiforme were treated with the GliaSite Radiation Therapy System (RTS).
  • CONCLUSIONS: GliaSite radiotherapy confers a prolongation of survival in patients with recurrent glioblastoma multiforme compared to historical controls with recurrent GBM.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Benzenesulfonates / therapeutic use. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Radiotherapy Dosage. Reoperation. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990019.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Iodine Radioisotopes; 0 / iotrex
  •  go-up   go-down


38. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K: An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand; 2008 Mar;117(3):191-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme.
  • Objectives - To explore the use of boron neutron capture therapy (BNCT) for patients with glioblastoma multiforme (GBM), recurring after surgery and conventional radiotherapy (photon radiotherapy).
  • BNCT was well tolerated and quality of life remained stable until tumor progression for all 12 patients.
  • No correlation was found between survival times and minimum tumor dose and number of radiation fields.
  • Conclusions - Boron neutron capture therapy, with the prolonged procedure for infusion, is at least as effective as other radiation therapies for recurrent GBM and is delivered in one treatment session, with low radiation dose to the healthy brain.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Body Weight. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297764.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


39. Rosati A, Marconi S, Pollo B, Tomassini A, Lovato L, Maderna E, Maier K, Schwartz A, Rizzuto N, Padovani A, Bonetti B: Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol; 2009 Jul;93(3):319-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels.
  • PURPOSE: The hypothesis addressed by this study is that a glutamine synthetase (GS) deficiency in neoplastic astrocytes is a possible molecular basis associated with seizure generation in glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / enzymology. Epilepsy / enzymology. Epilepsy / etiology. Glioblastoma / complications. Glioblastoma / enzymology. Glutamate-Ammonia Ligase / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.1.2 / Glutamate-Ammonia Ligase
  •  go-up   go-down


40. Ali K, Lu Y, Das U, Sharma RK, Wiebe S, Meguro K, Sadanand V, Fourney DR, Vitali A, Kelly M, May T, Gomez J, Pellerin E: Biomolecular diagnosis of human glioblastoma multiforme using Synchrotron mid-infrared spectromicroscopy. Int J Mol Med; 2010 Jul;26(1):11-6
Hazardous Substances Data Bank. CALCIUM FLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomolecular diagnosis of human glioblastoma multiforme using Synchrotron mid-infrared spectromicroscopy.
  • Glioblastoma multiforme (GBM) is one of the most malignant human tumors, with a uniformly poor outcome.
  • One obstacle in curing malignant brain tumors is the limitation of conventional light microscopy in detecting microscopic residual tumor in biopsy samples from the perimeter of the surgically resected tumor.
  • We further refined the identification of GBM tumor tissue at the sub-cellular level, utilising the technique of Synchrotron, sourced mid-infrared (mid-IR) spectromicroscopy.
  • Paired, thin (5 microm) cryosections of snap-frozen human GBM tumor samples removed at elective surgery were mounted on glass slides (hematoxylin and eosin-stained tissue section) and calcium fluoride (CaF2) windows (unstained tissue section for transmission spectromicroscopy), respectively.
  • Concordance of tumor bearing areas identified in the stained section with the unstained IR tissue section was confirmed by the pathologist of the study.
  • Compared with molecular signatures obtained from normal control brain tissue, unique spectroscopic patterns were detected in GBM tumor samples from 6 patients.
  • False color images of 5 clusters obtained by HCA identified dominant clusters corresponding to tumor tissue.
  • Corroboration of these findings in a larger number of GBM may allow for more precise identification of these and other types of brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Spectrophotometry, Infrared / methods. Synchrotrons
  • [MeSH-minor] Adult. Aged. Calcium Fluoride / chemistry. Child. Cluster Analysis. Cryoultramicrotomy / methods. Female. Histocytochemistry / methods. Humans. Lipids / analysis. Lipids / chemistry. Male. Middle Aged. Proteins / analysis. Proteins / chemistry

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514416.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Lipids; 0 / Proteins; O3B55K4YKI / Calcium Fluoride
  •  go-up   go-down


41. Parsa AT, Wachhorst S, Lamborn KR, Prados MD, McDermott MW, Berger MS, Chang SM: Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg; 2005 Apr;102(4):622-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults.
  • OBJECT: The clinical outcome and treatment of adult patients with disseminated intracranial glioblastoma multiforme (GBM) is unclear.
  • The objective in the present study was to assess the prognostic significance of disseminated intracranial GBM in adults at presentation and at the time of tumor progression.
  • Patients with dissemination at first tumor progression (52 patients) overall had a shorter PPS than those in a control group with local progression, after adjusting for age, Kamofsky Performance Scale score, and time from tumor diagnosis to its progression (311 patients).
  • When analyzed according to tumor dissemination type, PPS was significantly shorter in patients with Type II (33 patients, p < 0.01) and Type III spread (11 patients, p < 0.01) but not in those with Type I spread (eight patients, p = 0.18).
  • CONCLUSIONS: Apparently, the presence of intracranial tumor dissemination on initial diagnosis does not in itself preclude aggressive treatment if a patient is otherwise well.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871503.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13525; United States / NCI NIH HHS / CA / CA82103; United States / NINDS NIH HHS / NS / NS42927
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


42. Keir ST, Farland MM, Lipp ES, Friedman HS: Distress persists in long-term brain tumor survivors with glioblastoma multiforme. J Cancer Surviv; 2008 Dec;2(4):269-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distress persists in long-term brain tumor survivors with glioblastoma multiforme.
  • INTRODUCTION: Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor.
  • RESULTS: Eight-three brain tumor patients participated in this study.
  • CONCLUSIONS: This study indicates that LTS of GBM report experiencing distress at similar levels to other brain tumor patients.
  • [MeSH-major] Anxiety Disorders / epidemiology. Brain Neoplasms / psychology. Glioblastoma / psychology. Survivors
  • [MeSH-minor] Adult. Aged. Fatigue / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prevalence. Research Design


43. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, Goldfinger D, Ng H, Irvin D, Yu JS: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res; 2008 Jul 15;68(14):5955-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
  • Therapeutic vaccination represents an intriguing additional therapy for glioblastoma multiforme (GBM; grade 4 glioma), which has a dismal prognosis and treatment response, but only early phase I vaccine trial results have been reported.
  • Posttreatment times to tumor progression (TTP) and survival (TTS) were compared in vaccine responders and nonresponders and were correlated with immune response magnitudes.
  • This is the first report of a progressive correlation between cancer clinical outcome and T-cell responsiveness after therapeutic vaccination in humans and the first tracing of such correlation to therapeutically exploitable tumor alteration.
  • [MeSH-major] Brain Neoplasms / microbiology. Brain Neoplasms / therapy. Glioblastoma / immunology. Glioblastoma / therapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Cancer Vaccines. Dendritic Cells / immunology. Female. Humans. Immune System. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Polymerase Chain Reaction. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632651.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


44. Gross MW, Altscher R, Brandtner M, Haeusser-Mischlich H, Chiricuta IC, Siegmann AD, Engenhart-Cabillic R: Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. Clin Neurol Neurosurg; 2005 Apr;107(3):207-13
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
  • BACKGROUND: Due to its radioresistance, the prognosis of glioblastoma multiforme (GBM) remains poor.
  • CTC toxicity grade 3 was observed in six patients and grade 4 toxicity in two patients (three events).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Humans. Male. Middle Aged. Pilot Projects. Prospective Studies. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823676.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


45. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ: Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther; 2008 Apr;8(4):541-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
  • BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):777-85 [11901186.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Acta Radiol. 2002 Jul;43(4):354-9 [12225474.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20 [12234397.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):904-11 [16741298.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Cancer Res. 1991 Oct 15;51(20):5760-5 [1717153.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1593-607 [17134364.001]
  • [Cites] Hum Gene Ther. 2003 Jun 10;14(9):883-95 [12828859.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S35-40 [17145523.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 [17236958.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):141-50 [17115285.001]
  • [Cites] Neuroscience. 2007 Mar 30;145(3):795-811 [17320297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37 [17234361.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3449-59 [17575207.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7055-8 [17671170.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S116-9 [17512217.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):412-23 [17622648.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):733-6 [17882276.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5670-4 [17908955.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):635-41 [10682677.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1322-9 [11355942.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 [11504114.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6020-4 [11507045.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7501-6 [11606386.001]
  • [Cites] Science. 2002 Feb 1;295(5556):858-61 [11823643.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):236-41 [12517803.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5822-7 [7694795.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1317-26 [8167412.001]
  • [Cites] Lancet. 1994 Jul 9;344(8915):82-6 [7516992.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):520-9 [7525492.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7788-95 [8631822.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):3131-9 [9399960.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10820-5 [9724788.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):363-70 [15739567.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):558-65 [15705616.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4162-71 [15867205.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6270-9 [16144931.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8218-23 [16166297.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):452-64 [16212810.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8145-57 [16299247.001]
  • [Cites] Oncology. 2005;69 Suppl 3:11-6 [16301831.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):318-26 [16389944.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):409-17 [16484420.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1449-53 [16549839.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Clin Neurosurg. 2005;52:384-8 [16626098.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5018-22 [16951216.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Radiology. 2003 Aug;228(2):523-32 [12819338.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:169-77 [14531575.001]
  • [Cites] Mol Cancer Res. 2004 Jan;2(1):36-42 [14757844.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86 [15207817.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5 [15479484.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [CommentIn] Expert Opin Biol Ther. 2008 Oct;8(10):1449-53 [18774913.001]
  • (PMID = 18352856.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108786-029003; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NCI NIH HHS / CA / CA108786-059003; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / NS020023-268626; United States / NINDS NIH HHS / NS / NS020023-240020; United States / NINDS NIH HHS / NS / NS020023-220020; United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / P50 CA108786-039003; United States / NINDS NIH HHS / NS / NS020023-250020; United States / NINDS NIH HHS / NS / P50 NS020023-210020; United States / NCI NIH HHS / CA / CA108786-049003; United States / NCI NIH HHS / CA / P50 CA108786-059003; United States / NCI NIH HHS / CA / P50 CA108786-029003; United States / NINDS NIH HHS / NS / P50 NS020023-230020; United States / NCI NIH HHS / CA / CA108786-05S19003; United States / NCI NIH HHS / CA / P50 CA108786-049003; United States / NCI NIH HHS / CA / CA11898; United States / NCI NIH HHS / CA / CA108786-039003; United States / NINDS NIH HHS / NS / P50 NS020023-240020; United States / NINDS NIH HHS / NS / P50 NS020023-268626; United States / NCI NIH HHS / CA / P50 CA108786-019003; United States / NINDS NIH HHS / NS / P50 NS020023-220020; United States / NCI NIH HHS / CA / P50 CA108786-05S19003; United States / NCI NIH HHS / CA / CA108786-019003; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / P50 NS020023-250020; United States / NCI NIH HHS / CA / R37 CA011898; United States / NINDS NIH HHS / NS / NS020023-210020; United States / NINDS NIH HHS / NS / NS020023-230020
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 139
  • [Other-IDs] NLM/ NIHMS180495; NLM/ PMC2871667
  •  go-up   go-down


46. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, Gutin PH: Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery; 2009 May;64(5):819-26; discussion 826-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
  • OBJECTIVE: The neovascularization of malignant brain tumors is a poorly understood phenomenon.
  • Radiographic and histological evidence of increased vascularity correlate with clinical grade of gliomas.
  • Circulating endothelial progenitor cells are unique vascular precursors recruited from the bone marrow through the circulation to form new tumor blood vessels.
  • These cells were measured in patients undergoing surgery for glioblastoma multiforme (GBM).
  • We hypothesized that this might reflect the extent of tumor vascularity, predict prognosis, or be useful as an assay to assess response to antiangiogenesis therapies.
  • METHODS: Fifty-six patients with various-grade gliomas had peripheral venous blood collected at the time of surgery and at subsequent visits during the follow-up period.
  • RESULTS: Plasma derived from peripheral blood of patients with GBM scored significantly higher on the functional angiogenic scale compared with plasma derived from patients with low-grade gliomas and from controls.
  • In addition, all patients with GBM had measurable numbers of bone marrow-derived endothelial precursor cells coexpressing CD133 and vascular endothelial growth factor receptor 2 in their peripheral circulation at the time of tumor resection.
  • CONCLUSION: These studies suggest that plasma and circulating CD133+ vascular endothelial growth factor receptor 2+ proangiogenic cells are present in the peripheral blood of patients with glioma and can be used as a surrogate biomarker to measure tumor angiogenicity.
  • These assays can be used to predict tumor aggressiveness.
  • Also promising is their potential to identify patients with increased angiogenic activity who might respond maximally to antiangiogenesis therapies or to assess tumor response in patients using those therapies as the use of these adjuvant molecular modalities becomes more prevalent in neuro-oncology.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / blood. Glioblastoma / blood. Neovascularization, Pathologic / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Biological Assay / methods. Endothelial Cells / metabolism. Endothelial Cells / pathology. Enzyme-Linked Immunosorbent Assay / methods. Female. Flow Cytometry. Follow-Up Studies. Glycoproteins / metabolism. Humans. Male. Middle Aged. Peptides / metabolism. Stem Cells / metabolism. Stem Cells / pathology. Umbilical Veins / pathology. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biomark Med. 2010 Feb;4(1):127-8 [20387308.001]
  • (PMID = 19404145.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


47. Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M: Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res; 2005 Jul 15;65(14):6459-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms associated with asthma are inversely related to glioblastoma multiforme.
  • A reduced risk of primary malignant adult brain tumors is observed among people reporting asthma, hay fever, and other allergic conditions; however, findings may be attributed to prediagnostic effects of tumors or recall bias.
  • To determine whether asthma and allergic condition polymorphisms are inversely related to glioblastoma multiforme (GBM) risk, we conducted a population-based case-control study of 111 GBM patients and 422 controls.
  • Because we used germ line polymorphisms as biomarkers of susceptibility to asthma and allergic conditions, our results cannot be attributed to recall bias or effects of GBM on the immune system.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Mar 1;9(4):549-59 [10699178.001]
  • [Cites] Hum Mutat. 2004 Jul;24(1):1-8 [15221783.001]
  • [Cites] Nature. 1999 Nov 25;402(6760 Suppl):B2-4 [10586888.001]
  • [Cites] Cancer Immunol Immunother. 2000 Aug;49(6):319-24 [10946814.001]
  • [Cites] Genome Res. 2001 Jan;11(1):152-62 [11156624.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Sep;25(3):377-84 [11588017.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):230-6 [11709756.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1103-9 [11861389.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Annu Rev Immunol. 2003;21:425-56 [12615888.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:232-42 [12724228.001]
  • [Cites] Genome Res. 2003 May;13(5):916-24 [12727908.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):423-8 [12845684.001]
  • [Cites] Biotechniques. 2003 Aug;35(2):292-6, 298 [12951770.001]
  • [Cites] J Allergy Clin Immunol. 2003 Oct;112(4):717-22 [14564349.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Oct;132(2):168-76 [14600429.001]
  • [Cites] Cancer Immunol Immunother. 2004 Feb;53(2):79-85 [14610620.001]
  • [Cites] Clin Exp Allergy. 2004 Jan;34(1):26-31 [14720258.001]
  • [Cites] Respir Res. 2003;4:14 [14748924.001]
  • [Cites] Med Hypotheses. 2004;62(2):309-17 [14962646.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Glia. 2004 Apr 15;46(2):142-52 [15042582.001]
  • [Cites] J Clin Invest. 2004 Jun;113(11):1515-25 [15173875.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1131-9 [15191930.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e261-9 [12456313.001]
  • [Cites] Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):263-9 [15379594.001]
  • [Cites] Int J Epidemiol. 2004 Oct;33(5):945-6 [15319401.001]
  • [Cites] Cancer. 1992 May 15;69(10):2541-7 [1568177.001]
  • [Cites] Chest. 1993 Aug;104(2):600-8 [7802735.001]
  • [Cites] J Neuroimmunol. 1995 Jul;60(1-2):75-81 [7642750.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22428-33 [8798406.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):61-9 [8865004.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):664-72 [9259408.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1039-46 [9743522.001]
  • [Cites] Science. 1998 Dec 18;282(5397):2258-61 [9856949.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):87-8 [9920276.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):438-45 [10070943.001]
  • [Cites] Int J Cancer. 1999 Jul 19;82(2):155-60 [10389745.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1043-8 [15306533.001]
  • [Cites] Immunol Rev. 2004 Dec;202:191-202 [15546394.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8468-73 [15548720.001]
  • [Cites] Prog Neurol Surg. 2006;19:54-79 [17033147.001]
  • [Cites] Allergy. 2002 Feb;57(2):107-14 [11929412.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):252-9 [11979441.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1322-4, 1326, 1329 [12074163.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):426-30 [12110844.001]
  • [Cites] Genome Res. 2002 Sep;12(9):1401-7 [12213777.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 [12377741.001]
  • [CommentIn] Cancer Res. 2006 Mar 1;66(5):2878; author reply 2878-9 [16510612.001]
  • (PMID = 16024651.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA103379; United States / NCI NIH HHS / CA / R01CA103379
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / IL4R protein, human; 0 / Interleukin-13; 0 / Interleukin-4 Receptor alpha Subunit; 0 / Membrane Proteins; 0 / Receptors, Cell Surface; 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; 0 / Trans-Activators; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM33 protein, human; EC 3.4.24.- / Metalloendopeptidases
  • [Other-IDs] NLM/ NIHMS2295; NLM/ PMC1762912
  •  go-up   go-down


48. Piccirilli M, Salvati M, Bistazzoni S, Frati A, Brogna C, Giangaspero F, Frati R, Santoro A: Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Tumori; 2005 May-Jun;91(3):256-60
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks.
  • The association between breast cancer and glioblastoma multiforme has not been amply analyzed in the literature.
  • We describe 11 female patients with a diagnosis of glioblastoma multiforme who were treated when younger for breast cancer.
  • Another important point of view is represented by the chemotherapy treatment of breast cancer, which could have a carcinogenic effect and explain the growth of glioblastoma.
  • This consideration, in our opinion, is important, because more effort should be made to understand the pathogenesis of glioblastoma multiforme and to improve the therapeutic approaches.
  • [MeSH-major] Brain Neoplasms / etiology. Breast Neoplasms / complications. Glioblastoma / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasms, Second Primary. Time Factors


49. Martinez R, Rohde V, Schackert G: Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol; 2010 Feb;96(3):321-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.
  • One of the hallmarks of glioblastoma is its inherent tendency to recur.
  • In all tumor samples, we have analyzed p53 and PTEN status by sequencing analysis, EGFR amplification by semiquantitative PCR and a wide-genome fingerprinting was performed by microsatellite analysis.
  • Upon recurrence, we have detected two molecular patterns of tumor progression: GBM initially showing either type 1 or type 2 profiles conserved them at the time of relapse.
  • Taken together, our results strongly suggest that recurrences of GBM may display two distinct pattern of accumulation of molecular alterations depending on the profile of the original tumor.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glioblastoma / genetics. Mutation / genetics. PTEN Phosphohydrolase / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Am J Hum Genet. 2006 Nov;79(5):923-34 [17033968.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1264-8 [17272309.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):71-8 [18004504.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):934-41 [10551321.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] Hum Mutat. 2000;16(2):109-22 [10923032.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Mol Carcinog. 2000 Nov;29(3):143-50 [11108659.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):255-7 [11300334.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 1;132(1):20-4 [11801303.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):779-83 [12754350.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):82-90 [12784873.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1954-6 [14647431.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 May;75(5):723-6 [15090567.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6806-14 [15286718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):432-7 [1324297.001]
  • [Cites] Hum Genet. 1994 May;93(5):607-8 [8168846.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):813-8 [7947085.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):57-64 [7815080.001]
  • [Cites] J Neurooncol. 1994;21(2):151-7 [7861191.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):661-4 [8760309.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 19644652.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2811648
  •  go-up   go-down


50. Roth J, Constantini S, Blumenthal DT, Ram Z: The value of ventriculo-peritoneal shunting in patients with glioblastoma multiforme and ventriculomegaly. Acta Neurochir (Wien); 2008 Jan;150(1):41-6; discussion 46-7
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of ventriculo-peritoneal shunting in patients with glioblastoma multiforme and ventriculomegaly.
  • BACKGROUND: Patients with an advanced-stage glioblastoma multiforme (GBM) often show general motor, gait, and cognitive deterioration.
  • CONCLUSIONS: Insertion of a ventriculo-peritoneal shunt can improve cognitive and motor function in a small subset of patients with advanced-stage glioblastoma multiforme and ventriculomegaly.
  • [MeSH-major] Glioblastoma / surgery. Ventriculoperitoneal Shunt / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prosthesis-Related Infections / etiology. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180865.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


51. Karaca M, Andrieu MN, Hicsonmez A, Guney Y, Kurtman C: Cases of glioblastoma multiforme metastasizing to spinal cord. Neurol India; 2006 Dec;54(4):428-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cases of glioblastoma multiforme metastasizing to spinal cord.
  • Cases of glioblastoma multiforme (GBM) metastasizing to the leptomeninx or the intramedullary spine are quite rare and prognoses are relatively poor.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Meningeal Neoplasms / secondary. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114859.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Atukeren P, Kemerdere R, Kacira T, Hanimoglu H, Ozlen F, Yavuz B, Tanriverdi T, Gumustas K, Canbaz B: Expressions of some vital molecules: glioblastoma multiforme versus normal tissues. Neurol Res; 2010 Jun;32(5):492-501
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expressions of some vital molecules: glioblastoma multiforme versus normal tissues.
  • OBJECTIVE: The aim of this study was to assess plasma and/or tissue levels of adhesion and apoptotic molecules, cytokines, nitric oxide metabolites, levels of lipid peroxidation, myeloperoxidase and superoxide dismutase in patients with glioblastoma multiforme and controls.
  • METHODS: All the molecules were evaluated in 25 tumors and 30 controls: 15 were normal healthy subjects for plasma and 15 were normal brain tissues that were collected during autopsy.
  • DISCUSSION: These results suggest that there is a complex relationship between pro- and anti-apoptotic molecules in glioblastoma multiforme pathogenesis.
  • Thus, targeting multiple pathways with advanced chemotherapeutic agents or radiotheraupetic regimens following total resections might be helpful in patients with glioblastoma multiforme since preventing a single pathway does not seem to be reasonable.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / blood. Brain Neoplasms / metabolism. Glioblastoma / blood. Glioblastoma / metabolism
  • [MeSH-minor] Adult. Aged. Blood Chemical Analysis. Case-Control Studies. Child. Female. Humans. Male. Middle Aged. Young Adult


53. Culicchia F, Cui JG, Li YY, Lukiw WJ: Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme. Neuroreport; 2008 Jun 11;19(9):981-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of beta-amyloid precursor protein expression in glioblastoma multiforme.
  • Glioma and glioblastoma multiforme constitute rapidly proliferating glial cell tumors whose pathogenic mechanisms are not well understood.
  • This study examined proinflammatory and neurodegenerative gene expression in five American Tissue Culture Collection glioma and glioblastoma multiforme tumor cell lines and in 14 glioma and glioblastoma samples obtained from human brain biopsy.
  • These studies suggest that glioma and glioblastoma exhibit robust upregulation of proinflammatory and neurodegenerative genetic markers that may contribute to the pathobiology, phenotype, and proliferation of glial cell growth.
  • [MeSH-major] Amyloid beta-Protein Precursor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Up-Regulation / physiology
  • [MeSH-minor] Adult. Antigens, Human Platelet / genetics. Antigens, Human Platelet / metabolism. Cell Line, Tumor. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Female. Humans. Interleukin-1beta / metabolism. Male. Middle Aged. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521005.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Antigens, Human Platelet; 0 / Interleukin-1beta; 0 / RNA, Messenger; 0 / human platelet antigen 1b; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


54. Tuettenberg J, Grobholz R, Seiz M, Brockmann MA, Lohr F, Wenz F, Vajkoczy P: Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol; 2009 Sep;135(9):1239-44
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.
  • PURPOSE: Glioblastoma multiforme is the prototype of an angiogenic tumour.
  • Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy.
  • PATIENTS AND METHODS: A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804 [16585512.001]
  • [Cites] Tumori. 2007 Jan-Feb;93(1):31-6 [17455869.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1045-7 [10772648.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 [17306935.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6702-4 [1384969.001]
  • [Cites] J Neurosurg. 1983 Feb;58(2):159-69 [6294260.001]
  • [Cites] Lancet. 2004 Dec 4-10;364(9450):2021-9 [15582059.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):351-60 [15015668.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):221-32 [11801563.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7501-6 [11606386.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4934-40 [16000592.001]
  • [Cites] Curr Pharm Des. 2006;12(3):341-9 [16454748.001]
  • [Cites] Pathol Res Pract. 2000;196(5):277-84 [10834383.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93 [16860996.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Cancer Immunol Immunother. 2007 May;56(5):641-8 [16960692.001]
  • [Cites] Stem Cells Dev. 2007 Oct;16(5):837-47 [17999604.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1388-93 [10728704.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Invest New Drugs. 1997;15(1):39-48 [9195288.001]
  • [Cites] Radiother Oncol. 1999 Oct;53(1):53-7 [10624854.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4578-85 [14555533.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):177-85 [11716069.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1745-54 [17541035.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):335-42 [17504931.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):571-82 [10974478.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1537-60 [18020923.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):427-36 [11693902.001]
  • (PMID = 19277712.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


55. Hou LC, Bababeygy SR, Sarkissian V, Fisher PG, Vogel H, Barnes P, Huhn SL: Congenital glioblastoma multiforme: case report and review of the literature. Pediatr Neurosurg; 2008;44(4):304-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital glioblastoma multiforme: case report and review of the literature.
  • Congenital glioblastoma multiforme is a rare primary brain tumor that has a unique biology distinct from pediatric and adult variants.
  • In this report, we present a case of congenital glioblastoma with complicated management course.
  • Imaging studies revealed a large hemispheric tumor, resulting in significant midline shift suggestive of impending herniation.
  • Emergent tumor cystic fluid drainage was performed at initial presentation.
  • The patient eventually succumbed 4 months later due to aggressive tumor progression.
  • Congenital glioblastoma should be included in the differential diagnosis of infants with large intracranial tumors.
  • [MeSH-major] Glioblastoma / congenital

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18504417.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 39
  •  go-up   go-down


56. Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D: Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer; 2005 Nov 15;104(10):2168-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
  • METHODS: Thirty-two patients with recurrent glioblastoma multiforme (GBM) were treated for 36 lesions with SRS from 1993 to 2001.
  • The median age at primary diagnosis of the tumor was 56 years (range, 33-76 yrs).
  • Histology evaluations revealed glioblastoma multiforme (WHO Grade IV) in all 32 patients.
  • No acute toxicities > CTC Grade II occurred.
  • All patients died of tumor progression during follow-up.
  • The median overall survival from primary diagnosis of the tumor was 22 months (range, 9-133 mo).
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16220556.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Seker A, Ozek MM: Congenital glioblastoma multiforme. Case report and review of the literature. J Neurosurg; 2006 Dec;105(6 Suppl):473-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital glioblastoma multiforme. Case report and review of the literature.
  • The definition of a "congenital" tumor is controversial.
  • The authors report the case of a "definite" congenital glioblastoma multiforme (GBM) diagnosed with the aid of ultrasonography and fetal magnetic resonance (MR) imaging in the 37th week of gestation.
  • Postnatal MR imaging revealed a massive tumor occupying the patient's left temporoparietooccipital area.
  • Surgery was performed, and the tumor was successfully excised completely.
  • The histopathological diagnosis of the tumor was GBM.
  • An examination of the tumor cells revealed no p53 accumulation, a high MIB-1 index (87.5%), and no staining for epidermal growth factor receptor (EGFR).
  • Congenital GBM should be considered in the differential diagnosis in cases in which a fetal ultrasonography study or fetal MR image reveals a tumor, especially in the presence of intratumoral hemorrhage.
  • Radical tumor removal, administration of adjuvant therapy, and biological findings (such as a lack of the overexpression of p53 and EGFR in the tumor cells) all point to a longer survival time.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Glioblastoma / surgery. Glioblastoma / ultrasonography
  • [MeSH-minor] Adult. Cerebral Angiography. Female. Fetal Diseases / ultrasonography. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Pregnancy. Ultrasonography, Prenatal

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184081.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


58. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V: Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol; 2005 Aug;181(8):507-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
  • Since higher 2-DG doses are expected to improve the therapeutic gain, present studies were undertaken to examine the tolerance and safety of escalating 2-DG dose during combined treatment (2-DG + radiotherapy) in glioblastoma multiforme patients.
  • PATIENTS AND METHODS: Untreated patients with histologically proven glioblastoma multiforme (WHO criteria) were included in the study.
  • Seven weekly fractions of (60)Co gamma-rays (5 Gy/fraction) were delivered to the tumor volume (presurgical CT/MRI evaluation) plus 3 cm margin.
  • No significant damage to the normal brain tissue was observed during follow-up in seven out of ten patients who received complete treatment and survived between 11 and 46 months after treatment.
  • CONCLUSION: Oral administration of 2-DG combined with large fractions of radiation (5 Gy/fraction/week) is safe and could be tolerated in glioblastoma patients without any acute toxicity and late radiation damage to the normal brain.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Deoxyglucose / administration & dosage. Glioblastoma / radiotherapy. Radiopharmaceuticals / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Cobalt Radioisotopes / therapeutic use. Dose Fractionation. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044218.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Radiopharmaceuticals; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


59. Lucena Rde C, de Mello RJ, Lessa JR Jr, Cavalcante GM, Ribeiro M: [Clinical topographic findings in glioblastoma multiforme and the relation with motor impairment]. Arq Neuropsiquiatr; 2006 Jun;64(2B):441-5
MedlinePlus Health Information. consumer health - Movement Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical topographic findings in glioblastoma multiforme and the relation with motor impairment].
  • Glioblastoma multiforme (GBM) is the glial tumor with the highest grade of malignity.
  • It mainly affects the cerebral hemispheres, presenting general or focal signs and symptoms, which depend on the size, the location of the lesion and rate of growth of the tumor.
  • RESULTS: The occurrence of the tumor was preponderant in adults (mean age 55 years old), men (55.82%), and frontal lobe (approximately 40%).
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Movement Disorders / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917616.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


60. Ishikawa E, Tsuboi K, Yamamoto T, Muroi A, Takano S, Enomoto T, Matsumura A, Ohno T: Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci; 2007 Aug;98(8):1226-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients.
  • A pilot study was performed to investigate the safety and feasibility of autologous formalin-fixed tumor vaccines (AFTV) and the clinical responses to these vaccines by glioblastoma multiforme (GBM) patients.
  • Eight had recurrent disease while four had been treated for primary disease but retained a visible tumor mass.
  • AFTV were prepared from formalin-fixed and/or paraffin-embedded tumor tissue obtained upon surgery and premixed with original adjuvant materials.
  • In addition, the tumor tissues were subjected to immunohistochemical analysis to determine whether MIB-1, p53, and major histocompatibility complex (MHC) class-I complex expression could predict the response to the treatment.
  • The treatment was well tolerated, with only local erythema, induration, and low-grade fever being reported.
  • Low p53 and high MHC class-I expression by the tumor may help predict the efficacy of this therapy.
  • [MeSH-major] Cancer Vaccines. Glioblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / therapy. Feasibility Studies. Female. Fixatives. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Pilot Projects. Predictive Value of Tests. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517052.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Fixatives
  •  go-up   go-down


61. Gallego JM, Barcia JA, Barcia-Mariño C: Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien); 2007 Mar;149(3):261-5; discussion 265
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal outcome related to carmustine implants in glioblastoma multiforme.
  • We report three cases in whom patients with glioblastoma multiforme were implanted with fibrin glue-secured Gliadel after the lateral ventricles had been opened, and who later developed severe hydrocephalus leading to death.
  • [MeSH-major] Antineoplastic Agents, Alkylating / toxicity. Brain Neoplasms / drug therapy. Carmustine / toxicity. Glioblastoma / drug therapy. Hydrocephalus / chemically induced. Temporal Lobe / surgery
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Drug Implants. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Reoperation. Ventriculostomy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334672.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Drug Implants; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  •  go-up   go-down


62. Utsuki S, Tanaka S, Oka H, Iwamoto K, Sagiuchi T, Fujii K: Glioblastoma multiforme metastasis to the axis. Case report. J Neurosurg; 2005 Mar;102(3):540-2
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme metastasis to the axis. Case report.
  • Extracranial bone metastasis from glioblastoma multiforme (GBM) has rarely been reported in the literature, and most metastatic GBMs are multiple bone metastases.
  • Magnetic resonance imaging demonstrated a right temporal tumor, which was diagnosed as a GBM based on tumor resection.
  • Magnetic resonance studies revealed a tumor in the axis that was diagnosed as GBM based on biopsy procedure.
  • [MeSH-major] Axis, Cervical Vertebra. Brain Neoplasms / pathology. Glioblastoma / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796392.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Riva M, Imbesi F, Beghi E, Galli C, Citterio A, Trapani P, Sterzi R, Collice M: Temozolomide and thalidomide in the treatment of glioblastoma multiforme. Anticancer Res; 2007 Mar-Apr;27(2):1067-71
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and thalidomide in the treatment of glioblastoma multiforme.
  • OBJECTIVE: The aim of this study was to assess efficacy and toxicity of temozolomide given alone or in combination with thalidomide, an anti-angiogenetic drug, in patients with newly diagnosed glioblastoma multiforme (GBM).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465245.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


64. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart-Cabillic R, An HX: Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep; 2008 Jan;19(1):151-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
  • Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor characterized by excessive angiogenesis.
  • The EphA2 receptor tyrosine kinase plays a pivotal role in tumor angiogenesis and an increased expression in glioma patients has recently been reported.
  • In this study, we investigated the expression of EphA2 in human normal brain, primary and recurrent GBM and correlated it with clinical pathological parameters and patient's outcome.
  • A different intensity of the membranous and cytoplastic expression of EphA2 was observed in the 40 primary and recurrent samples of GBM analyzed but not in the normal brain.
  • The data presented in this study define the expression pattern of EphA2 in both primary and recurrent glioblastoma and suggest an important role of EphA2 in the pathogenesis of GBM.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Receptor, EphA2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neovascularization, Pathologic. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097589.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


65. Prayson NF, Angelov L, Prayson RA: Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis. Ann Diagn Pathol; 2009 Oct;13(5):291-6
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis.
  • Patients with glioblastoma multiforme (GBM) are known to be at risk for hypercoagulable events.
  • The purpose of this study was to assess whether there is a relationship between the number of thrombi identified microscopically at the time of tumor resection and the subsequent development of extremity deep venous thrombosis (DVT).
  • A retrospective review of 96 patients (53 men and 43 women; age range, 21-92 years; mean age, 60.2 years) with GBM (World Health Organization grade IV) was carried out.
  • Thrombi were counted (number of thrombi/blood vessels evaluated/10 high-power fields) in nonnecrotic areas of the resected tumor and correlated with a variety of clinical and pathological parameters, including the development of postoperative DVT, as detected by extremity ultrasound.
  • Eighty-one patients died of tumor (survival, 1-66 months; mean, 11.0 months), 12 patients were alive at last known follow-up (mean, 23 months), and 3 patients were lost to follow-up.
  • Of patients with DVT, 27 patients died of tumor (survival, 1-47 months; mean, 11.0 months), 3 patients were alive (18, 20, and 21 months), and 1 patient was lost to follow-up.
  • There was no correlation between the number of microscopic thrombi and the percentage of resected tumor that was necrotic (range, <5%-90%), presence of palisaded necrosis (36.8% of tumors), presurgical (mean, 78.3) or postsurgical (mean, 75.5) Karnofsky performance scores, or survival (mean, 8.9 months in patients with no microscopic thrombi vs 11.5 months in patients with thrombi).
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Venous Thrombosis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ohio / epidemiology. Prognosis. Retrospective Studies. Survival Rate. Ultrasonography. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751904.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Klautke G, Schütze M, Bombor I, Benecke R, Piek J, Fietkau R: Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. J Neurooncol; 2006 Apr;77(2):199-205
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme.
  • PURPOSE: The prognosis for patients with glioblastoma multiforme remains poor.
  • RESULT: Haematological toxicities were 13/42 (30%) grade III leucopenia, 2/42 (4%) grade IV, as well as 5/42 (10%) grade III thrombopenias and 1/42 (2%) grade IV.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Topotecan / adverse effects
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314953.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


67. Necesalová E, Vranová V, Kuglík P, Cejpek P, Jarosová M, Pesáková M, Relichová J, Veselská R: Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology. Neoplasma; 2007;54(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology.
  • Glioblastoma multiforme (GBM) is the most common as well as the most aggressive type of primary brain tumor of astrocytic origin in adults.
  • Trisomy/polysomy of chromosome 7, monosomy of chromosome 10, EGFR gene amplification and p53 deletion have been described as the typical genetic markers for tumor classification and prediction of possible response to therapy.
  • Our work was based on detection of these four main genetic changes both in central and peripheral parts of the tumors to evaluate possible differences in the topological incidence of these genetic markers.
  • Chromosomal abnormalities in tumor samples from a group of 21 patients surgically treated for GBM were characterized by means of the interphase-fluorescence in situ hybridization (I-FISH) technique using sets of centromere and locus-specific DNA probes.
  • In addition, we performed a detailed analysis of one selected tumor sample using a genomic microarray system (GenoSensor Array 300) to characterize copy number changes of specific sequences and refine results obtained by I-FISH.
  • However, the data show no significant differences in occurrence of the described genetic markers in either part of the tumor.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 10 / genetics. Glioblastoma / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Chromosome Aberrations. Chromosome Mapping. Female. Gene Amplification. Gene Dosage. Genetic Markers / genetics. Humans. In Situ Hybridization, Fluorescence. Incidence. Karyotyping. Male. Middle Aged. Nucleic Acid Hybridization. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447852.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


68. Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, Lickliter JD: Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci; 2010 Aug;17(8):970-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.
  • Relapsed glioblastoma multiforme (GBM) responds poorly to standard therapies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioblastoma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20541421.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


69. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • The aim of this study was to assess HIF-1alpha in 22 patients with transitional meningioma (TM) and 26 patients with glioblastoma multiforme (GBM).
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


70. Brown RE, Law A: Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. Ann Clin Lab Sci; 2006;36(4):421-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications.
  • Glioblastoma multiforme (GBM) presents a major challenge to neurosurgeons, neuro-oncologists, and radiation therapists by virtue of its location with a blood-brain barrier, chemoradioresistance, highly malignant phenotype, and angiogenic potential.
  • Furthermore, such constitutive activation of the NF-kappaB pathway helps to explain some of the tumor biology and supports the incorporation of NF-kappaB pathway inhibitors into the treatment of GBM.
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Nucleus / metabolism. Glioblastoma / metabolism. NF-kappa B / biosynthesis. Proteomics. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. DNA / genetics. DNA / metabolism. Female. Gene Expression Regulation. Humans. Male. Middle Aged. Phosphorylation

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127728.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 9007-49-2 / DNA
  •  go-up   go-down


71. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M: Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol; 2006 Jul;78(3):295-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.
  • PATIENTS AND METHODS: A total of 162 patients with intracranial glioblastoma multiforme or gliosarcomas who had undergone surgery and radiotherapy participated in this multicenter, double-blind, placebo-controlled, parallel group study conducted at 20 institutions.
  • Seventy-nine patients (57 male, 22 female, median age 58 years) were randomized to receive placebo (PB), and 83 patients (51 male, 32 female, median age 57 years) were randomized to receive MT, 10 mg orally twice daily, until tumor progression.
  • CONCLUSION: MT does not improve survival in patients with glioblastoma or gliosarcoma following surgery and radiotherapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Hydroxamic Acids / therapeutic use. Matrix Metalloproteinase Inhibitors
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Double-Blind Method. Female. Humans. Male. Matrix Metalloproteinases / metabolism. Middle Aged. Musculoskeletal Diseases / chemically induced. Quality of Life. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636750.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; 0 / Matrix Metalloproteinase Inhibitors; D5EQV23TDS / marimastat; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


72. Schuhmann MU, Zucht HD, Nassimi R, Heine G, Schneekloth CG, Stuerenburg HJ, Selle H: Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol; 2010 Feb;36(2):201-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme.
  • AIMS: To apply modern mass spectrometry based technology to identify possible CSF peptide markers of glioblastoma multiforme (GBM).
  • Using both, we analyzed CSF samples of 11 patients harbouring a glioblastoma multiforme in comparison to 13 normal controls.
  • CONCLUSION: The study showed that peptidomics technology is able to identify possible biomarkers of neoplastic CNS disease.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Glioblastoma / cerebrospinal fluid. Peptides / cerebrospinal fluid. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Supratentorial Neoplasms / cerebrospinal fluid
  • [MeSH-minor] Adult. Aged. Albumins / cerebrospinal fluid. Chromatography, High Pressure Liquid. Female. Humans. Male. Middle Aged. Osteopontin / cerebrospinal fluid. Peptide Fragments. Prealbumin / cerebrospinal fluid. Proteomics / methods. alpha 1-Antichymotrypsin / cerebrospinal fluid

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19674866.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Albumins; 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Peptides; 0 / Prealbumin; 0 / alpha 1-Antichymotrypsin; 106441-73-0 / Osteopontin
  •  go-up   go-down


73. Sköld K, H-Stenstam B, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW: Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol Scand; 2010 Jul;122(1):58-62
Hazardous Substances Data Bank. BORON COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f.
  • OBJECTIVES: To assess possible improved efficacy of Boron Neutron Capture Therapy (BNCT) for glioblastoma multiforme (GBM) using prolonged infusion and a correspondingly higher dose of l-boronophenylalanine, as the fructose complex (BPA-f).
  • The fraction of patients with WHO grade 3-4 adverse events was similar in the two studies at 13% and 14%, respectively.
  • [MeSH-major] Boron Compounds / administration & dosage. Boron Neutron Capture Therapy. Fructose / analogs & derivatives. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Middle Aged. Salvage Therapy. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951268.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / 4-boronophenylalanine-fructose; 0 / Boron Compounds; 30237-26-4 / Fructose
  •  go-up   go-down


74. Mahajan A, McCutcheon IE, Suki D, Chang EL, Hassenbusch SJ, Weinberg JS, Shiu A, Maor MH, Woo SY: Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg; 2005 Aug;103(2):210-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme.
  • OBJECT: The role of stereotactic radiosurgery (SRS) for recurrent glioblastoma multiforme (GBM) was evaluated in a case-control study.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175848.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Paldino MJ, Barboriak D, Desjardins A, Friedman HS, Vredenburgh JJ: Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. J Magn Reson Imaging; 2009 May;29(5):1199-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.
  • PURPOSE: To quantify the repeatability of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in patients with glioblastoma multiforme.
  • Sixteen patients with glioblastoma multiforme underwent MR imaging at two time points without interval intervention.
  • Volumes of tumor-related enhancement (TRE) and FLAIR signal abnormality (FSA) were defined using a semiautomated segmentation technique.
  • [MeSH-major] Algorithms. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Image Interpretation, Computer-Assisted / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388113.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Martinez R, Schackert HK, Appelt H, Plaschke J, Baretton G, Schackert G: Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol; 2005 Feb;131(2):87-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme.
  • PURPOSE: Genetic instability is a hallmark of glioblastoma multiforme (GBM).
  • RESULTS: MSI was observed in six GBMs (5.5%) and it was more frequent in GBMs with a previous lower grade astrocytoma (18.8% vs. 3.2%).
  • Among MSI(+) GBMs, one tumor corresponded to the GBM molecular type 1 (p53 mutation, no EGFR amplification), another tumor to type 2 (wild-type p53, EGFR amplification), and four tumors to neither type (wild-type p53, no EGFR amplification).
  • [MeSH-major] Base Pair Mismatch / genetics. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioblastoma / genetics. Glioblastoma / pathology. Microsatellite Repeats / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Transformation, Neoplastic. DNA Damage. DNA Repair. Female. Humans. Immunohistochemistry. Male. Middle Aged. Phenotype

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1635-41 [9488480.001]
  • [Cites] Adv Cancer Res. 1997;71:93-119 [9111864.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):16-25 [10918389.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1547-9 [7882363.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):369-75 [10945812.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):853-7 [9284834.001]
  • [Cites] Brain Pathol. 1993 Jan;3(1):19-26 [8269081.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5556-60 [7585634.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):242-8 [7812952.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):152-6 [8162069.001]
  • [Cites] Cancer Lett. 1997 Jan 30;112(2):161-6 [9066723.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8568-73 [9671718.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):57-64 [7815080.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4750-5 [8062274.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):813-8 [7947085.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):643-8 [11807791.001]
  • [Cites] Int J Colorectal Dis. 1999 Nov;14(4-5):194-200 [10647627.001]
  • [Cites] Glia. 1995 Nov;15(3):328-38 [8586467.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12 ):2736-9 [8504413.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):601-7 [8882883.001]
  • (PMID = 15672285.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


77. Singh PK, Singh VK, Tomar J, Azam A, Gupta S, Kumar S: Spinal glioblastoma multiforme: unusual cause of post-traumatic tetraparesis. J Spinal Cord Med; 2009;32(5):583-6
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioblastoma multiforme: unusual cause of post-traumatic tetraparesis.
  • BACKGROUND/OBJECTIVE: Glioblastoma multiforme (GBM) is the most common glial cell tumor of the adult brain.
  • A magnetic resonance scan showed the typical appearance of a high-grade intramedullary tumor with fusiform expansion of the entire cervical cord.
  • CONCLUSIONS: This presentation of GBM of the cervical cord is rare; an intramedullary tumor should be considered when minor cervical trauma results in disproportionate neurologic deficit.
  • [MeSH-major] Glioblastoma / complications. Quadriplegia / etiology. Quadriplegia / therapy. Spinal Neoplasms / complications
  • [MeSH-minor] Decompression, Surgical. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Radiotherapy. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] No Shinkei Geka. 1985 Mar;13(3):301-5 [2989721.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • [Cites] No Shinkei Geka. 1992 Jan;20(1):85-9 [1310803.001]
  • [Cites] Arch Neurol. 1978 Apr;35(4):244-5 [205201.001]
  • [Cites] Radiology. 1965 Mar;84:401-8 [14283212.001]
  • [Cites] Spinal Cord. 2005 Sep;43(9):565-7 [15838531.001]
  • [Cites] Acta Oncol. 2006;45(1):87-90 [16464801.001]
  • [Cites] J Neurosurg Spine. 2007 Dec;7(6):656-9 [18074692.001]
  • [Cites] Rinsho Shinkeigaku. 1995 Nov;35(11):1235-40 [8720335.001]
  • (PMID = 20025156.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2792466
  •  go-up   go-down


78. Belda-Iniesta C, Carpeño Jde C, Saenz EC, Gutiérrez M, Perona R, Barón MG: Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol Ther; 2006 Aug;5(8):912-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term responses with cetuximab therapy in glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is responsible for most of the deaths associated with primary brain tumors.
  • Cetuximab is a monoclonal antibody targeted against the extra cellular domain of the EGFR with activity against different tumor types, either alone or in combination with chemotherapy and/or radiation therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Female. Humans. Magnetic Resonance Imaging. Male. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2006 Sep;5(9):1242-3 [17035733.001]
  • (PMID = 16929166.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


79. Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, Wan YL: Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol; 2008 Mar;29(3):471-5
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging.
  • BACKGROUND AND PURPOSE: Differentiating between primary cerebral lymphoma and glioblastoma multiforme (GBM) based on conventional MR imaging sequences may be impossible.
  • Regions of interest were placed in only solid-enhancing tumor areas and the contralateral normal-appearing white matter (NAWM) to measure the FA and ADC values.
  • The differences in FA and ADC between lymphoma and GBM, as well as between solid-enhancing areas of each tumor type and contralateral NAWM, were analyzed statistically.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / diagnosis. Image Interpretation, Computer-Assisted / methods. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065516.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW: Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res; 2010 Jan;30(1):253-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prognostic value of CD44 in glioblastoma multiforme.
  • BACKGROUND/AIM: Glioblastoma and astrocytoma are the most common brain tumors affecting adults 45-60 years of age.
  • The poor prognosis for glioblastoma patients results from recurrence after treatment.
  • PATIENTS AND METHODS: Microarray analyses of clinical specimens from glioblastoma patients were used to identify potential tumor markers.
  • In particular, expression of the CD44 antigen was elevated in more severe tumor types, and higher in tumor cores than in peripheral regions.
  • [MeSH-major] Antigens, CD44 / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics
  • [MeSH-minor] Adult. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150644.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human
  •  go-up   go-down


81. Welsh JW, Ellsworth RK, Kumar R, Fjerstad K, Martinez J, Nagel RB, Eschbacher J, Stea B: Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1251-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rad51 protein expression and survival in patients with glioblastoma multiforme.
  • PURPOSE: Treatment of glioblastoma multiforme (GBM) continues to pose a significant therapeutic challenge, with most tumors recurring within the previously irradiated tumor bed.
  • Rad51, an enzyme involved in homologous recombinational repair, leads to increased resistance of tumor cells to cytotoxic treatments such as radiotherapy.
  • METHODS AND MATERIALS: A total of 68 patients with an initial diagnosis of GBM were retrospectively evaluated; for 10 of these patients, recurrent tumor specimens were used to construct a tissue microarray.
  • CONCLUSION: Elevated levels of the double-stranded DNA repair protein Rad51 predicted for an increase survival duration in patients with GBM, at both initial tumor presentation and disease recurrence.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545791.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA02307
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; EC 2.7.7.- / Rad51 Recombinase
  •  go-up   go-down


82. Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T, Relichova J: Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer; 2006;6:32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in the cell lines derived from glioblastoma multiforme.
  • BACKGROUND: Nestin is a protein belonging to class VI of intermediate filaments that is produced in stem/progenitor cells in the mammalian CNS during development and is consecutively replaced by other intermediate filament proteins (neurofilaments, GFAP).
  • Down-regulated nestin may be re-expressed in the adult organism under certain pathological conditions (brain injury, ischemia, inflammation, neoplastic transformation).
  • Our work focused on a detailed study of the nestin cytoskeleton in cell lines derived from glioblastoma multiforme, because re-expression of nestin together with down-regulation of GFAP has been previously reported in this type of brain tumor.
  • METHODS: Two cell lines were derived from the tumor tissue of patients treated for glioblastoma multiforme.
  • RESULTS: Using epifluorescence and confocal microscopy, we described the morphology of nestin-positive intermediate filaments in glioblastoma cells of both primary cultures and the derived cell lines, as well as the reorganization of nestin during mitosis.
  • CONCLUSION: Detailed information concerning the pattern of the nestin cytoskeleton in glioblastoma cell lines and especially the demonstration of nestin in the nucleus represent an important background for further studies of nestin re-expression in relationship to tumor malignancy and invasive potential.
  • [MeSH-major] Glioblastoma / chemistry. Intermediate Filament Proteins / analysis. Nerve Tissue Proteins / analysis
  • [MeSH-minor] Cell Line, Tumor. Cytoskeleton / chemistry. Cytoskeleton / ultrastructure. Fluorescent Antibody Technique, Indirect. Glial Fibrillary Acidic Protein / analysis. Humans. Nestin. Vimentin / analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):503-15 [10571412.001]
  • [Cites] Exp Cell Res. 2003 Apr 1;284(2):185-95 [12651152.001]
  • [Cites] Exp Cell Res. 2000 Feb 1;254(2):269-78 [10640425.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1468-78 [12686602.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(14):5090-106 [12832492.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):520-32 [14965445.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):52-6 [15031671.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):27994-9 [15117961.001]
  • [Cites] J Neurosci. 1985 Dec;5(12):3310-28 [4078630.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] J Cell Sci. 1992 Oct;103 ( Pt 2):589-97 [1478958.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):354-6 [8275467.001]
  • [Cites] Exp Cell Res. 1994 Oct;214(2):447-58 [7925640.001]
  • [Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]
  • [Cites] Brain Res Dev Brain Res. 1995 Jan 14;84(1):109-29 [7720210.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):188-98 [8569181.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 Nov-Dec;17(6):913-25 [9353831.001]
  • [Cites] J Struct Biol. 1997 Oct;120(1):61-8 [9356292.001]
  • [Cites] Pediatr Res. 1998 Mar;43(3):386-92 [9505279.001]
  • [Cites] Exp Cell Res. 1998 Mar 15;239(2):332-43 [9521851.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1157-68 [9777947.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23996-4006 [10446168.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):665-71 [15736068.001]
  • [Cites] J Cell Sci. 1998 Dec 18;111 ( Pt 24):3573-84 [9819349.001]
  • [Cites] Curr Opin Cell Biol. 2000 Feb;12(1):79-90 [10679360.001]
  • [Cites] Exp Neurol. 2000 Feb;161(2):585-96 [10686078.001]
  • [Cites] Int J Dev Neurosci. 2001 Feb;19(1):101-8 [11226759.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):817-23 [11238030.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16456-63 [11278541.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):6147-58 [11487638.001]
  • [Cites] Stem Cells. 2001;19(5):419-24 [11553850.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):641-55 [12209758.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):775-85 [12239616.001]
  • [Cites] Neurosci Res. 2002 Oct;44(2):207-12 [12354635.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • (PMID = 16457706.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vimentin
  • [Other-IDs] NLM/ PMC1403792
  •  go-up   go-down


83. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res; 2008 May 15;14(10):3098-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
  • PURPOSE: To investigate the therapeutic role of adjuvant vaccination with autologous mature dendritic cells (DC) loaded with tumor lysates derived from autologous, resected glioblastoma multiforme (GBM) at time of relapse.
  • EXPERIMENTAL DESIGN: Fifty-six patients with relapsed GBM (WHO grade IV) were treated with at least three vaccinations.
  • A trend to improved PFS was observed in favor of the faster DC vaccination schedule with tumor lysate boosting.
  • [MeSH-major] Antigens, Neoplasm / therapeutic use. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Dendritic Cells / immunology. Glioblastoma / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Postoperative Period

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483377.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


84. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery; 2008 Mar;62(3):564-76; discussion 564-76
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.
  • OBJECTIVE: The influence of the degree of resection on survival in patients with glioblastoma multiforme is still under discussion.
  • METHODS: Two hundred forty-three patients with glioblastoma multiforme per protocol from the 5-aminolevulinic acid study were analyzed.
  • Prognostic factors that might cause bias regarding resection and influence survival (e.g., tumor size, edema, midline shift, location, age, Karnofsky Performance Scale score, National Institutes of Health Stroke Scale score) were used for analysis of overall survival.
  • RESULTS: Treatment bias was identified in patients with complete (n = 122) compared with incomplete resection (n = 121), i.e., younger age and less frequent eloquent tumor location.
  • Other factors, foremost preoperative tumor size, were identical.
  • Patients without residual tumor survived longer (16.7 versus 11.8 mo, P < 0.0001).
  • In multivariate analysis, only residual tumor, age, and Karnofsky Performance Scale score were significantly prognostic.
  • Reinterventions occurred marginally earlier in patients with residual tumor (6.7 versus 9.5 mo, P = 0.0582).
  • However, bias and imbalances were controllable in the cohorts available from the 5-aminolevulinic acid study so that the present data now provide Level 2b evidence (Oxford Centre for Evidence-based Medicine) that survival depends on complete resection of enhancing tumor in glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Glioblastoma / mortality. Glioblastoma / surgery. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Bias (Epidemiology). Disease-Free Survival. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2009 Jun;64(6):E1206; author reply E1206 [19487874.001]
  • (PMID = 18425006.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Oppel F; Brune A; Lanksch W; Woiciechowsky C; Brock M; Vesper J; Tonn JC; Goetz C; Gilsbach JM; Mayfrank L; Oertel MF; Seifert V; Franz K; Bink A; Schackert G; Pinzer T; Hassler W; Bani A; Meisel HJ; Kern BC; Mehdorn HM; Nabavi A; Brawanski A; Ullrich OW; Böker DK; Winking M; Weber F; Langenbach U; Westphal M; Kähler U; Arnold H; Knopp U; Grumme T; Stretz T; Stolke D; Wiedemayer H; Turowski B; Pietsch T; Wiestler OD; Reulen HJ; Stummer W
  •  go-up   go-down


85. Lipani JD, Jackson PS, Soltys SG, Sato K, Adler JR: Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme. Technol Cancer Res Treat; 2008 Jun;7(3):249-55
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
  • Current therapeutic goals for treatment of Glioblastoma Multiforme (GBM) involve gross total resection followed by multifractionated focal external beam radiation therapy (EBRT).
  • The treated tumor volumes ranged from 9.62 cm(3)-185.81 cm(3) (mean: 86.08 cm(3)).
  • Median survival of patients in Recursive Partitioning Analysis (RPA) classes III or IV was 32 months versus 12 months for those in RPA class V.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Glioblastoma / radiotherapy. Glioblastoma / surgery. Radiosurgery. Radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose Fractionation. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Nimustine / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473497.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0S726V972K / Nimustine; 5J49Q6B70F / Vincristine
  •  go-up   go-down


86. Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM, van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman AM, Giaccone G, Peters GJ: Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol; 2009 Jan;20(1):182-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
  • Glioblastoma multiforme (GBM), the most frequent malignant brain tumor, has a poor prognosis, but is relatively sensitive to radiation.
  • The aim of this phase 0 study was to investigate whether gemcitabine passes the blood-tumor barrier, and is phosphorylated in the tumor by deoxycytidine kinase (dCK) to gemcitabine nucleotides in order to enable radiosensitization, and whether it is deaminated by deoxycytidine deaminase (dCDA) to dFdU.
  • Tumor gemcitabine and dFdU levels varied from 60 to 3580 pmol/g tissue and from 29 to 72 nmol/g tissue, respectively.
  • These data demonstrate for the first time that gemcitabine passes the blood-tumor barrier in GBM patients.
  • In tumor samples, both gemcitabine and dFdU concentrations are high enough to enable radiosensitization, which warrants clinical studies using gemcitabine in combination with radiation.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701427.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 039LU44I5M / Floxuridine; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.5.4.- / Nucleoside Deaminases; EC 3.5.4.5 / Cytidine Deaminase; EC 3.5.4.5 / deoxycytidine deaminase
  •  go-up   go-down


87. Seiz M, Nölte I, Pechlivanis I, Freyschlag CF, Schmieder K, Vajkoczy P, Tuettenberg J: Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. Neurosurg Rev; 2010 Jul;33(3):375-81; discussion 381
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
  • Glioblastoma multiforme is the most common and most malignant primary brain tumour.
  • Here, we describe extreme far-distant metastases along the neural axis of glioblastoma multiforme in four patients receiving metronomic antiangiogenic chemotherapy and review the literature to discuss possible mechanisms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / pathology. Central Nervous System Neoplasms / secondary. Cerebrospinal Fluid. Dacarbazine / analogs & derivatives. Glioblastoma / pathology. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Celecoxib. Combined Modality Therapy. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minim Invasive Neurosurg. 2001 Sep;44(3):175-7 [11696889.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):1011-2 [10526085.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804 [16585512.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):337-76 [12663862.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1159-66 [7653994.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Neoplasia. 2008 Dec;10 (12 ):1383-92 [19048117.001]
  • [Cites] Cancer. 1978 Dec;42(6):2854-64 [215298.001]
  • [Cites] Br J Neurosurg. 2008 Jun;22(3):452-5 [18568742.001]
  • [Cites] Can J Surg. 1959 Jul;2(4):363-5 [13662922.001]
  • [Cites] J Neurosurg. 1983 Feb;58(2):159-69 [6294260.001]
  • [Cites] J Neurosurg. 2005 Mar;102(3):540-2 [15796392.001]
  • [Cites] J Neurosurg. 1961 May;18:313-30 [13761772.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):64-71 [1738457.001]
  • [Cites] Pediatr Neurosurg. 1999 Nov;31(5):242-5 [10681678.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40 [15565458.001]
  • [Cites] Strahlenther Onkol. 2004 Jul;180(7):455-7 [15241534.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4934-40 [16000592.001]
  • [Cites] Curr Pharm Des. 2006;12(3):341-9 [16454748.001]
  • [Cites] Neurosurg Rev. 2000 Mar;23(1):39-44 [10809486.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):348-51 [16455543.001]
  • [Cites] Clin Neuropathol. 2005 Nov-Dec;24(6):247-51 [16320817.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):167-71 [11859971.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Sep;135(9):1239-44 [19277712.001]
  • [Cites] Clin Imaging. 1994 Oct-Dec;18(4):386-9 [8000959.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):318-24 [2056977.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):141-8 [11508813.001]
  • [Cites] Neurosurgery. 1990 Oct;27(4):516-21; discussion 521-2 [2172859.001]
  • [Cites] J Neurosurg. 2000 Nov;93(5):887-90 [11059674.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:283-323 [11807174.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):627-37 [185169.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):227-35 [12675316.001]
  • [Cites] J Clin Neurosci. 2006 Jul;13(6):677-81 [16815020.001]
  • (PMID = 20306105.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Pyrazoles; 0 / Sulfonamides; 7GR28W0FJI / Dacarbazine; JCX84Q7J1L / Celecoxib; YF1K15M17Y / temozolomide
  •  go-up   go-down


88. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK: Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol; 2008 Apr;10(2):216-22
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
  • This phase II study aimed at determining the efficacy and safety of irinotecan combined with thalidomide in adults with recurrent glioblastoma multiforme (GBM) not taking enzyme-inducing anticonvulsants (EIACs).
  • Adult patients (> or =18 years) with recurrent GBM with up to three relapses following surgery and radiation therapy were eligible for this trial.
  • Adverse events (grade 3 or 4) included diarrhea, abdominal cramps, lymphopenia, neutropenia, and fatigue.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Lancet. 2000 Aug 12;356(9229):566-7 [10950238.001]
  • [Cites] Oncology (Williston Park). 2000 Dec;14(12 Suppl 13):29-32 [11204671.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1614-5 [11520815.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):33-40 [12199631.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2352-8 [12712456.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Oncology (Williston Park). 2003 May;17(5 Suppl 5):9-14 [12800600.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):33-8 [14758131.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Treat Res. 2004;117:307-36 [15015567.001]
  • [Cites] Neuro Oncol. 2004 Apr;6(2):134-44 [15134628.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):417-23 [9054955.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1592-6 [9389920.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4779-86 [15570079.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Surg Pathol. 2005 Apr;13(2):215-8 [15864388.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):420-2 [16680743.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • (PMID = 18314417.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2613824
  •  go-up   go-down


89. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, Paglierani M, Pollo B, Taddei GL, Gallina P, Di Lorenzo N, Franceschetti S, Wanke E, Arcangeli A: hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer; 2005 Oct 3;93(7):781-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines.
  • The expression pattern of these two channels was compared to that of the classical inward rectifying K(+) channels, IRK, that are widely expressed in astrocytic cells and classically considered a marker of astrocytic differentiation.
  • In our study, hERG1 was found to be specifically overexpressed in high-grade astrocytomas, that is, glioblastoma multiforme (GBM).
  • In addition, we present evidence that, in GBM cell lines, hERG1 channel activity actively contributes to malignancy by promoting vascular endothelial growth factor secretion, thus stimulating the neoangiogenesis typical of high-grade gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Potassium Channels, Voltage-Gated / metabolism. Vascular Endothelial Growth Factor A / secretion
  • [MeSH-minor] Adult. Aged. Base Sequence. Cell Line, Tumor. Child. DNA Primers. Ether-A-Go-Go Potassium Channels. Female. Humans. Immunohistochemistry. Male. Middle Aged. Patch-Clamp Techniques. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 7;286(5):857-62 [11527377.001]
  • [Cites] Mol Biol Cell. 2005 Jun;16(6):2972-83 [15800067.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Xenobiotica. 2001 Aug-Sep;31(8-9):633-50 [11569530.001]
  • [Cites] Pflugers Arch. 2002 May;444(1-2):186-92 [11976931.001]
  • [Cites] Eur J Neurosci. 2002 Aug;16(3):415-28 [12193184.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1791-8 [12200695.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] Pathol Res Pract. 2002;198(9):627-33; discussion 635-8 [12440786.001]
  • [Cites] Br J Pharmacol. 2003 Jan;138(1):161-71 [12522086.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2947-55 [12431979.001]
  • [Cites] FASEB J. 2003 Feb;17(2):330-2 [12490549.001]
  • [Cites] Pflugers Arch. 2003 Feb;445(5):589-600 [12634931.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] J Neurosci. 2003 Jul 2;23(13):5572-82 [12843258.001]
  • [Cites] Drug News Perspect. 2003 Jun;16(5):291-8 [12942160.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Gene Expr Patterns. 2003 Dec;3(6):767-76 [14643686.001]
  • [Cites] J Clin Pathol. 2003 Dec;56(12):972-5 [14645363.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):606-11 [14744775.001]
  • [Cites] Glia. 2004 Apr 1;46(1):63-73 [14999814.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Mol Pharmacol. 2004 May;65(5):1120-9 [15102940.001]
  • [Cites] Cancer Cell. 2004 May;5(5):405-6 [15144945.001]
  • [Cites] Neurosci Lett. 2004 Sep 30;368(3):249-53 [15364405.001]
  • [Cites] J Exp Ther Oncol. 2004 Jul;4(2):161-6 [15500011.001]
  • [Cites] Crit Rev Neurobiol. 1991;6(2):119-47 [1934088.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3438-42 [8159766.001]
  • [Cites] J Physiol. 1995 Dec 1;489 ( Pt 2):455-71 [8847640.001]
  • [Cites] J Physiol. 1996 Oct 1;496 ( Pt 1):13-23 [8910192.001]
  • [Cites] J Neurophysiol. 1998 May;79(5):2782-93 [9582244.001]
  • [Cites] J Neurobiol. 1999 Mar;38(4):466-74 [10084682.001]
  • [Cites] FASEB J. 2000 Dec;14(15):2601-10 [11099479.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1722-9 [11104572.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6868-74 [11156382.001]
  • [Cites] J Neurophysiol. 2001 Feb;85(2):790-803 [11160513.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4923-31 [11080495.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neurosci. 2001 Jul 1;21(13):4609-24 [11425889.001]
  • [Cites] Eur J Neurosci. 1999 Mar;11(3):753-60 [10103069.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 1):C1405-10 [10362604.001]
  • [Cites] J Neurosci. 1999 Jul 15;19(14):5942-54 [10407033.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):445-9 [10448297.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):25018-25 [10455180.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • (PMID = 16175187.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / ERG1 potassium channel; 0 / Ether-A-Go-Go Potassium Channels; 0 / Potassium Channels, Voltage-Gated; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2361632
  •  go-up   go-down


90. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol; 2010 Aug 20;28(24):3838-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scale to predict survival after surgery for recurrent glioblastoma multiforme.
  • PURPOSE: Despite initial treatment with surgical resection, radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) virtually always recurs.
  • In this study, we sought to devise a preoperative scale that predicts survival after surgery for recurrent glioblastoma multiforme.
  • RESULTS: The factors associated with poor postoperative survival were: tumor involvement of prespecified eloquent/critical brain regions (P = .021), Karnofsky performance status (KPS) < or = 80 (P = .030), and tumor volume > or = 50 cm(3) (P = .048).
  • CONCLUSION: We devised and validated a preoperative scale that identifies patients likely to have poor, intermediate, and good relative outcomes after surgical resection of a recurrent GBM tumor.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Pharmacol Ther. 2010 Oct;128(1):1-36 [20546782.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):607-14 [2827051.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):709-20; discussion 720-3 [9574634.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Neurosurg. 2008 Nov;109(5):817-24 [18976070.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] N Engl J Med. 2010 Jan 21;362(3):e6 [20054035.001]
  • [CommentIn] J Clin Oncol. 2011 Feb 1;29(4):e102; author reply e103 [21172889.001]
  • (PMID = 20644085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940401
  •  go-up   go-down


91. Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML: Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol; 2006 Apr 1;24(10):1627-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation.
  • PURPOSE: Glioblastoma multiforme (GBM) is the most common and aggressive glioma with the poorest survival.
  • [MeSH-major] DNA-Binding Proteins / genetics. Glioblastoma / genetics. Glioblastoma / mortality. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Female. Genetic Variation. Genotype. Humans. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-100264; United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / CA-70917; United States / NIEHS NIH HHS / ES / ES-11740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


92. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa A: Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg; 2009 Mar;110(3):583-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
  • OBJECT: Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Biocompatible Materials / administration & dosage. Carmustine / administration & dosage. Dacarbazine / analogs & derivatives. Decanoic Acids / administration & dosage. Glioblastoma / therapy. Polyesters / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046047.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biocompatible Materials; 0 / Decanoic Acids; 0 / Polyesters; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS780618; NLM/ PMC4856017
  •  go-up   go-down


93. Il'yasova D, Marcello JE, McCoy L, Rice T, Wrensch M: Total dietary antioxidant index and survival in patients with glioblastoma multiforme. Cancer Causes Control; 2009 Oct;20(8):1255-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total dietary antioxidant index and survival in patients with glioblastoma multiforme.
  • METHODS: The study population includes 814 glioblastoma multiforme cases that were newly diagnosed, histologically confirmed, aged 20 or older, and residing in the San Francisco Bay Area at diagnosis.
  • Cases were identified via the regional cancer registry's rapid case ascertainment system during 1991-1994 (series I), 1997-2000 (series II), and 2001-2004 (series III).

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 1999 Dec;27(11-12):1334-45 [10641728.001]
  • [Cites] Free Radic Biol Med. 2008 Oct 15;45(8):1178-89 [18718523.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):647-55 [12296512.001]
  • [Cites] J Occup Environ Med. 2003 Jun;45(6):639-47 [12802217.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):461-7 [15006924.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2618-25 [15102663.001]
  • [Cites] Redox Rep. 2004;9(3):145-52 [15327744.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):43-6 [8570130.001]
  • [Cites] J Neurooncol. 1996 Aug;29(2):121-8 [8858516.001]
  • [Cites] Biochem Soc Trans. 1996 Aug;24(3):790-5 [8878849.001]
  • [Cites] Cancer Causes Control. 1997 Jan;8(1):13-24 [9051318.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):20-3 [10077146.001]
  • [Cites] Neuroepidemiology. 1999;18(3):156-66 [10202269.001]
  • [Cites] Integr Cancer Ther. 2004 Dec;3(4):294-300 [15523100.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] BMC Cancer. 2006;6:148 [16749939.001]
  • [Cites] Nat Clin Pract Neurol. 2005 Dec;1(2):88-95 [16932504.001]
  • [Cites] J Nutr. 2007 Jan;137(1):93-8 [17182807.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):197-205 [17200355.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Free Radic Biol Med. 2007 Mar 15;42(6):787-97 [17320761.001]
  • [Cites] Clin Neuropathol. 2007 Sep-Oct;26(5):210-8 [17907597.001]
  • [Cites] Am J Clin Nutr. 2008 May;87(5):1247-53 [18469246.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):288-95 [18412241.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):773-83 [18505970.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Free Radic Biol Med. 2000 Apr 1;28(7):1143-56 [10832077.001]
  • (PMID = 19363672.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / CA52689; United States / NCI NIH HHS / CA / CA108786-04; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants
  • [Other-IDs] NLM/ NIHMS465445; NLM/ PMC3660721
  •  go-up   go-down


94. van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A: Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol; 2010 Jan;96(2):249-57
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.
  • Temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiforme since 2005.
  • Concomitant treatment with radiotherapy and temozolomide followed by adjuvant temozolomide resulted in grade III or IV haematological toxic effects in 9% of patients.
  • The addition of temozolomide to radiotherapy in routine clinical practice for newly diagnosed glioblastoma resulted in a clinically meaningful survival benefit with minimal haematological toxicity, which confirms the experience of previous trials and justifies the continued use of temozolomide in routine clinical practice.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Central Nervous System Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy / methods. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2000 Nov;57(2):131-6 [11054516.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Anticancer Drugs. 2003 Jul;14(6):447-8 [12853887.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):524-31 [2912529.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):1-9 [2661738.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):22-9 [2049748.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2372-7 [15800329.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Mar;18(2):93-103 [16523808.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):397-406 [17516742.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):339-43 [17579810.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76 [18425006.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):733-9 [19114694.001]
  • [Cites] J Neurosurg. 1993 May;78(5):762-6 [8385709.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):895-8 [8598367.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 19582373.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2808536
  •  go-up   go-down


95. Sell M, Huber-Schumacher S, van Landeghem FK: Congenital glioblastoma multiforme with abnormal vascularity presenting as intracranial hemorrhage in prenatal ultrasound. Childs Nerv Syst; 2006 Jul;22(7):729-33
MedlinePlus Health Information. consumer health - Fetal Health and Development.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital glioblastoma multiforme with abnormal vascularity presenting as intracranial hemorrhage in prenatal ultrasound.
  • BACKGROUND: A rare case of a congenital brain neoplasm with intratumoral massive hemorrhage suggested by prenatal ultrasound examination in a 32-week gestational age male fetus is reported.
  • METHODS: Autopsy disclosed a large well-delimited tumor with a sponge-like appearance due to high vascularization, which involved nearly the whole left cerebral hemisphere and led to marked hydrocephalus by secondary aqueductal stenosis.
  • Histological and immunohistochemical examination confirmed the diagnosis of a malignant glioma with features of a glioblastoma multiforme (GBM) matching well with previous findings in primary pediatric GBMs.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Fetal Diseases / diagnostic imaging. Glioblastoma / diagnostic imaging. Intracranial Hemorrhages / diagnostic imaging. Ultrasonography, Prenatal / methods
  • [MeSH-minor] Adult. Female. Fetus. Humans. Male. Pregnancy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Geburtshilfe Neonatol. 2002 Jan-Feb;206(1):19-21 [11887251.001]
  • [Cites] J Neurol Sci. 2001 Jul 15;188(1-2):13-9 [11489279.001]
  • [Cites] Prenat Diagn. 1997 Oct;17 (10 ):967-71 [9358578.001]
  • [Cites] Neuropadiatrie. 1973 Jan;4(1):46-63 [4739778.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] J Neuropathol Exp Neurol. 1964 Apr;23:280-92 [14137675.001]
  • [Cites] Childs Nerv Syst. 2003 Nov;19(10-11):778-81 [13680296.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):604-9 [3047342.001]
  • [Cites] Childs Nerv Syst. 1990 Mar;6(2):79-85 [2340533.001]
  • [Cites] J Clin Ultrasound. 1985 Jun;13(5):345-6 [3924967.001]
  • [Cites] J Neurooncol. 1984;2(2):113-6 [6541244.001]
  • [Cites] Arch Pathol Lab Med. 1982 Jan;106(1):31-4 [6274272.001]
  • [Cites] Neurosurgery. 1991 Jul;29(1):8-13 [1651461.001]
  • [Cites] Childs Nerv Syst. 1995 May;11(5):311-3 [7648575.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):97-9 [8420358.001]
  • [Cites] Childs Nerv Syst. 1999 Apr;15(4):197-201 [10361971.001]
  • [Cites] J Ultrasound Med. 1997 Apr;16(4):285-8 [9315158.001]
  • [Cites] Fetal Ther. 1987;2(4):203-8 [2855459.001]
  • [Cites] Brain Pathol. 2000 Apr;10 (2):249-59 [10764044.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1987 Summer;9(2):121-9 [3035957.001]
  • [Cites] Surg Neurol. 1987 Feb;27(2):163-7 [3810444.001]
  • [Cites] Bull Los Angel Neuro Soc. 1956 Mar;21(1):30-6 [13329555.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • (PMID = 16673148.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Stelzer KJ, Douglas JG, Mankoff DA, Silbergeld DL, Krohn KA, Laramore GE, Spence AM: Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme. Neuro Oncol; 2008 Feb;10(1):88-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge.
  • Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning.
  • Median progression-free survival was 16 weeks, and all patients had tumor progression by 39 weeks.
  • Treatment was clinically well tolerated, but evidence of mild to moderate gliosis and microvascular sclerosis consistent with radiation injury was observed at autopsy in specimens taken from regions of contralateral brain that received approximately 6-10 Gy.
  • Fast neutron radiation using modern imaging, treatment planning, and beam delivery was feasible to a total dose of 18 Gy, but tumor control probability was poor in comparison to that predicted from a dose-response model based on older studies.
  • Steep dose-response curves for both tumor control and neurotoxicity continue to present a challenge to establishing a therapeutic window for fast neutron radiation in GBM, even with modern techniques.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1635-42 [11896114.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1667-73 [12468518.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):1-12 [207833.001]
  • [Cites] Cancer. 1978 Jul;42(1):96-103 [96933.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):261-6 [6248495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):679-86 [2984151.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1093-102 [2838442.001]
  • [Cites] Med Dosim. 1991 Sep;16(3):137-41 [1910470.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Neurooncol. 1997 May;33(1-2):171-8 [9151234.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95 [9457811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):886-91 [16242251.001]
  • (PMID = 18055860.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA042045; United States / NCI NIH HHS / CA / P01 CA 42045
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 40871-47-4 / 2-fluoro-2-deoxyglucose-6-phosphate; 56-73-5 / Glucose-6-Phosphate
  • [Other-IDs] NLM/ PMC2600842
  •  go-up   go-down


97. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G: BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer; 2010;10:30
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.
  • BACKGROUND: The prognosis for patients with recurrent glioblastoma is still poor with a median survival between 3 and 6 months.
  • Reports about the application of carmustine (BCNU), one of the standard chemotherapeutic drugs in the treatment of newly diagnosed glioblastoma, in the recurrent situation are rare.
  • METHODS: We performed a retrospective analysis of 35 patients with recurrent or progressive glioblastoma treated with 80 mg/m2 BCNU on days 1 on 3 intravenously at our department for efficacy, toxicity and prognostic factors.
  • The influence of age, Karnofsky performance status (KPS), tumor burden, pretreatment with temozolomide (TMZ), type of surgery for initial diagnosis and number of previous relapses on outcome was analyzed in a proportional hazards regression model.
  • No influence of age, KPS, tumor burden, pre-treatment with TMZ and number of previous relapses on outcome could be demonstrated, while gross total resection prior to recurrence showed a borderline statistically significant negative impact on PFS and OS.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Carmustine / pharmacology. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1998 Feb;168(2):114-20 [9499745.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9 [15990019.001]
  • [Cites] J Neurosurg. 2005 Aug;103(2):210-7 [16175848.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2168-73 [16220556.001]
  • [Cites] Semin Radiat Oncol. 2006 Jan;16(1):29-37 [16378904.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E5 [16709036.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):453-61 [18452856.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):57-62 [19212704.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):161-71 [11508816.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neurology. 2004 Jun 8;62(11):2113-5 [15184628.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Mutat Res. 1985 Jan-Mar;145(1-2):1-16 [3883145.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):654-8 [3021931.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):607-14 [2827051.001]
  • [Cites] J Neurosurg. 1989 Apr;70(4):573-7 [2926498.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):583-91 [1429079.001]
  • [Cites] Clin Neuropathol. 1999 Jan-Feb;18(1):1-8 [9988132.001]
  • (PMID = 20122270.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2837009
  •  go-up   go-down


98. Habermeyer B, Weiland M, Mager R, Wiesbeck GA, Wurst FM: A clinical lesson: glioblastoma multiforme masquerading as depression in a chronic alcoholic. Alcohol Alcohol; 2008 Jan-Feb;43(1):31-3
MedlinePlus Health Information. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical lesson: glioblastoma multiforme masquerading as depression in a chronic alcoholic.
  • METHOD: We report the case of a 34-year-old male alcoholic, who presented with clinical depression and later a delirious state, and was subsequently diagnosed to have a right frontal glioblastoma multiforme.
  • [MeSH-major] Alcoholism / diagnosis. Brain Neoplasms / diagnosis. Depression / diagnosis. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male


99. Di Ieva A, Grizzi F, Tschabitscher M, Colombo P, Casali M, Simonelli M, Widhalm G, Muzzio PC, Matula C, Chiti A, Rodriguez y Baena R: Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings. Microvasc Res; 2010 Sep;80(2):267-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings.
  • Neuroradiological and metabolic imaging is a fundamental diagnostic procedure in the assessment of patients with primary and metastatic brain tumors.
  • The correlation between objective parameters capable of quantifying the neoplastic angioarchitecture and imaging data may improve our understanding of the underlying physiopathology and make it possible to evaluate treatment efficacy in brain tumors.
  • Only a few studies have so far correlated the quantitative parameters measuring the neovascularity of brain tumors with the metabolic profiles measured by means of amino acid uptake in positron emission tomography (PET) scans.
  • In this study, we evaluated the microvascular network complexity of six cases of human glioblastoma multiforme quantifying the surface fractal dimension on CD34 immunostained specimens.
  • The different fractal dimension values observed showed that the same histological category of brain tumor had different microvascular network architectures.
  • Our preliminary findings indicate that that vascularity (estimated on the histologic specimens by means of the fractal dimension) and (11)C-methionine uptake (assessed by PET) closely correlate in glioblastoma multiforme and that microvascular fractal dimension can be a useful parameter to objectively describe and quantify the geometrical complexity of the microangioarchitecture in glioblastoma multiforme.
  • [MeSH-major] Carbon Radioisotopes / pharmacokinetics. Glioblastoma / pathology. Methionine / pharmacokinetics. Microvessels / pathology. Neovascularization, Pathologic / pathology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Biological Transport. Female. Fractals. Humans. Image Processing, Computer-Assisted. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20394759.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


100. Farray D, Ahluwalia MS, Snyder J, Barnett GH, Cohen BH, Suh JH, Peereboom DM: Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Invest New Drugs; 2006 May;24(3):177-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.
  • PURPOSE: To evaluate the efficacy of 9-amino [20s] camptothecin (9-AC) given before radiation therapy to patients with newly diagnosed glioblastoma multiforme (GBM).
  • METHODS: Eligible patients had newly diagnosed GBM who had residual measurable contrast-enhancing tumor.
  • The most common adverse event was transient lymphopenia (grade 3-4).
  • One patient developed grade 4 neutropenic fever that resolved after three days of diagnosis.
  • CONCLUSIONS: 9-AC lacks activity against glioblastoma multiforme (GBM).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086097.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5MB77ICE2Q / 9-aminocamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement